[Frontiers in Bioscience 2, d619-634, December 15, 1997]

	[Frontiers in Bioscience 2, d619-634, December 15, 1997] Reprints PubMed CAVEAT LECTOR
	HUMAN IMMUNODEFICIENCY VIRUS TYPE I AS A TARGET FOR GENE THERAPY Magnús Gottfredsson and Paul R. Bohjanen Division of Infectious Diseases and International Health, Department of Medicine, Duke University Medical Center, Durham, NC 27710 Received 11/17/97 Accepted 11/24/97 8. REFERENCES 1. Mertens, T. E. and D. Low-Beer: HIV and AIDS: where is the epidemic going? Bull World Health Organ 74, 121-9 (1996) 2. Cavert, W., D. W. Notermans, K. Gebhard, K. Henry, Z.-Q. Zhang, R. Mills, H. McDade, J. Goudsmit, S. A. Danner and A. T. Haase: Kinetics of response in lymphoid tissues to antiretroviral therapy of HIV-1 infection. Science 276, 960-964 (1997) 3. Gulick, R.M., J. W. Mellors, D. Havlir, J. J. Eron, C. Gonzalez, D. McMahon, D. D. Richman, F. T. Valentine, L. Jonas, A. Meibohm, E. A. Emini and J. A. Chodakewitz: Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 337, 734-9 (1997) 4. Ho, D. D., A. U. Neumann, A. S. Perelson, W. Chen, J. M. Leonard and M. Markowitz: Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 373, 123-126 (1995) 5. Wei, X., S. K. Ghosh, M. E. Taylor, V. A. Johnson, E. A. Emini, P. Deutsch, J. D. Lifson, S. Bonhoeffer, M. A. Nowak, B. H. Hahn, M. S. Saag and G. M. Shaw: Viral dynamics in human immunodeficiency virus type 1 infection. Nature 373, 117-122 (1995) 6. Maddon, P.J., A. G. Dalgleish, J. S. McDougal, P. R. Clapham, R. A. Weiss and R. Axel: The T4 gene encodes the AIDS virus receptor and is expressed in the immune system and the brain. Cell 47, 333-348 (1986) 7. Dalgleish, A. G., P. C. L. Beverley, P. R. Clapham, D. H. Crawford, M. F. Greaves and R. A. Weiss: The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus. Nature 312, 763-767 (1984) 8. Klatzman, D., E. Champagne, S. Chamaret, J. Gruest, S. Guetard, T. Hercend, J.-C. Gluckman and L. Montagnier: T lymphocyte T4 molecule behaves as the receptor for human retrovirus LAV. Nature 312, 767-768 (1984) 9. Alkhatib, G., C. Combardiere, C. C. Broder, Y. Feng, P. E. Kennedy, P. M. Murphy and E. A. Berger: CC CKR5: A RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1. Science 272, 1955-1958 (1996) 10. Choe, H., M. Farzan, Y. Sun, N. Sullivan, B. Rollins, P. D. Ponath, L. Wu, C. R. Mackay, G. LaRosa, W. Newman, N. Gerard, C. Gerard and J. Sodorski: The ß-Chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. Cell 85, 1135-1148 (1996) 11. Deng, H., R. Liu, W. Ellmeier, S. Choe, D. Unutmaz, M. Burkhart, P. Marzio, S. Marmon, R. E. Sutton, C. M. Hill, C. B. Davis, P. S. C, T. J. Schall, D. R. Littman and N. R. Landau: Identification of a major co-receptor for primary isolates of HIV-1. Nature 381, 661-666 (1996) 12. Doranz, B. J., J. Rucker, Y. Yi, R. J. Smyth, M. Samson, S. C. Peiper, M. Parmentier, R. G. Collman and R. W. Doms: A dual-tropic primary HIV-1 isolate that uses Fusin and the ß-Chemokine receptors CKR-5, CKR-3, and CKR-2b as Fusion cofactors. Cell 85, 1149-1158 (1996) 13. Dragic, T., V. Litwin, G. P. Allaway, S. R. Martin, Y. Huang, K. A. Nagashima, C. Cayanan, P. J. Maddon, R. A. Koup, J. P. Moore and W. A. Paxton: HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature 381, 667-673 (1996) 14. Feng, Y., C. C. Broder, P. E. Kennedy and E. A. Berger: HIV-1 entry cofactor: Functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science 272, 872-877 (1996) 15. Berson, J. F., D. Long, B. J. Dorantz, J. Rucker, F. R. Jirik and R. W. Doms: A seven transmembrane domain receptor involved in fusion and entry of T-cell-tropic human immunodeficiency virus type 1 strains. J Virol 70, 6288-6295 (1996) 16. Schuitemaker, H., M. Koot, N. A. Koostra, W. Dercksen, R. E. Y. De Goude, R. P. Van Steenwijk, J. M. A. Lange, J. K. M. Eeftink Schattenkerk, F. Miedema and M. Tersmette: Biological phenotype of Human Immunodeficiency Virus Type 1 clones at different stages of infection: Progression of disease is associated with a shift from monocytotropic to T-cell tropic virus populations. J Virol 66, 1354-1360 (1992) 17. Connor, R. I. and D. D. Ho: Human Immunodeficiency Virus Type 1 variants with increased replicative capacity develop during the asymptomatic stage before disease progression. J Virol 68, 4400-4408 (1994) 18. Zhu, T., H. Mo, N. Wang, D. S. Nam, Y. Cao, R. A. Koup and D. D. Ho: Genotypic and phenotypic characterization of HIV-1 in patients with primary infection. Science 261, 1179-1181 (1993) 19. Trono, D: HIV accessory proteins: Leading roles for the supporting cast. Cell 82, 189-192 (1995) 20. Miller, R. H., S. R. Turk, R. J. Black, S. Bridges and N. Sarver: Conference summary: Novel HIV therapies - from discovery to clinical proof of concept. AIDS Res Hum Retroviruses 12, 859-865 (1996) 21. Heinzinger, N. K., M. I. Bukrinsky, S. A. Haggerty, A. M. Ragland, V. Kewalramani, M.-A. Lee, H. E. Gendelman, L. Ratner, M. Stevenson and M. Emerman: The Vpr protein of human immunodeficiency virus type 1 influences nuclear localization of viral nucleic acids in nondividing host cells. Proc Natl Acad Sci USA 91, 7311-7315 (1994) 22. Miller, R. H. and N. Sarver: HIV accessory proteins as therapeutic targets. Nature Med 4, 389-394 (1997) 23. Karn, J: An introduction to the growth cycle of human immunodeficiency virus. In: HIV. Biochemistry, molecular biology, and drug discovery. Ed: Karn, J., Oxford University Press, Oxford (1995) 24. Farnet, C. M. and F. D. Bushman: HIV-1 cDNA integration: Requirement of HMG I(Y) protein for function of preintegration complexes in vitro. Cell 88, 483-492 (1997) 25. Buchschacher, G.L., Jr: Molecular targets of gene transfer therapy for HIV infection. JAMA 269, 2880-2886 (1993) 26. Jones, K. A. and B. M. Peterlin: Control of RNA initiation and elongation at the HIV-1 promoter. Annu Rev Biochem 1994. 63, 717-743 (1994) 27. Karn, J., M. J. Churcher, K. Rittner, N. J. Keen and M. J. Gait: Control of transcriptional elongation by the human immunodeficiency virus Tat protein. In: Eukaryotic Gene Transcription. Ed: Goodbourn, S., Oxford University Press, Oxford (1996) 28. Arya, S. K., C. Guo, S. F. Josephs and F. Wong-Staal: Trans-activator gene of human T-lymphotropic virus typre III (HTLV-III). Science 229, 69-73 (1985) 29. Cullen, B. R: Trans-activation of human immunodeficiency virus occurs via a bimodal mechanism. Cell 46, 973-982 (1986) 30. Feng, S. and E. C. Holland: HIV-1 tat trans-activation requires the loop sequence within tar. Nature 334, 165-167 (1988) 31. Kao, S. Y., A. F. Calman, P. A. Luciw and B. M. Peterlin: Anti-termination of transcription within the long terminal repeat of HIV-1 by tat gene product. Nature 330, 489-493 (1987) 32. Keen, N. J., M. J. Gait and J. Karn: Human immunodeficiency virus type-1 Tat is an integral component of the activated transcription-elongation complex. Proc Natl Acad Sci U S A 93, 2505-2510 (1996) 33. Ratnasabapathy, A. R., M. Sheldon, L. Johal and N. Hernandez: The HIV-1 long terminal repeat contains an unusual element that induces the synthesis of short RNAs from various mRNA and snRNA promoters. Genes Dev 4, 2061-2074 (1990) 34. Toohey, M. G. and K. A. Jones: In vitro formation of short RNA polymerase II transcripts that terminate within the HIV-1 and HIV-2 promoter-proximal downstream regions. Genes Dev 3, 265-282 (1989) 35. Kashanchi, F., G. Piras, M. F. Radonovich, J. F. Duvall, A. Fattaey, C. M. Chiang, R. G. Roeder and J. N. Brady: Direct interaction of human TFIID with the HIV-1 transactivator tat. Nature 367, 295-299 (1994) 36. Jeang, K. T., R. Chun, N. H. Lin, A. Gatignol, C. G. Glabe and H. Fan: In vitro and in vivo binding of human immunodeficiency virus type 1 Tat protein and Sp1 transcription factor. J Virol 67, 6224-6233 (1993) 37. Parada, C. A. and R. G. Roeder: Enhanced processivity of RNA polymerase II triggered by Tat-induced phosphorylation of its carboxy-terminal domain. Nature 384, 375-378 (1996) 38. Mavankal, G., S. H. Ignatius Ou, H. Oliver, D. Sigman and R. B. Gaynor: Human immunodeficiency virus type 1 and 2 Tat proteins specifically interact with RNA polymerase II. Proc Natl Acad Sci U S A 93, 2089-2094 (1996) 39. Garcia-Martinez, L. F., D. Ivanov and R. B. Gaynor: Association of Tat with purified HIV-1 and HIV-2 transcription preinitiation complexes. J Biol Chem 272, 6851-6958 (1997) 40. Suñé, C., T. Hayashi, Y. Liu, W. S. Lane, R. A. Young and M. A. Garcia-Blanco: CA150, a nuclear protein associated with the RNA polymerase II holoenzyme, is involved in Tat-activated HIV-1 transcription. Mol Cell Biol 17, 6029-6039 (1997) 41. Cujec, T. P., H. Cho, E. Maldonado, J. Meyer, D. Reinberg and B. M. Peterlin: The human immunodeficiency virus transactivator Tat interacts with the RNA polymerase II holoenzyme. Mol Cell Biol 17, 1817-1823 (1997) 42. Colvin, R. A. and M. A. Garcia-Blanco: Unusual structure of the human immunodeficiency virus type 1 trans-activation response element. J Virol. 66, 930-935 (1992) 43. Colvin, R. A., S. W. White, M. A. Garcia-Blanco and D. W. Hoffman: Structural features of an RNA containing the CUGGGA loop of the human immunodeficiency virus type 1 trans-activation response element. Biochemistry 32, 1105-1112 (1993) 44. Harper, J. W. and N. J. Logsdon: Refolded HIV-1 tat protein protects both bulge and loop nucleotides in TAR RNA from ribonucleolytic cleavage. Biochemistry 30, 8060-8066 (1991) 45. Jaeger, J. A. and I. J. Tinoco: An NMR study of the HIV-1 TAR element hairpin. Biochemistry 32, 12522-12530 (1993) 46. Puglisi, J. D., R. Tan, B. J. Calnan, A. D. Frankel and J. R. Williamson: Conformation of the TAR RNA-arginine complex by NMR spectroscopy. Science 257, 76-80 (1992) 47. Calnan, B. J., B. Tidor, S. Biancalana, D. Hudson and A. D. Frankel: Arginine-mediated RNA recognition: the arginine fork. Science 252, 1167-1171 (1991) 48. Roy, S., U. Delling, C. H. Chen, C. A. Rosen and N. Sonenberg: A bulge structure in HIV-1 TAR RNA is required for Tat binding and Tat-mediated trans-activation. Genes Dev 4, 1365-1373 (1990) 49. Weeks, K. M., C. Ampe, S. C. Schultz, T. A. Steitz and D. M. Crothers: Fragments of the HIV-1 Tat protein specifically bind TAR RNA. Science 249, 1281-1285 (1990) 50. Garcia, J. A., D. Harrich, E. Soultanakis, F. Wu, R. Mitsuyasu and R. B. Gaynor: Human immunodeficiency virus type 1 LTR TATA and TAR region sequences required for transcriptional regulation. EMBO J 8, 765-778 (1989) 51. Gaynor, R., E. Soultanakis, M. Kuwabara, J. Garcia and D. S. Sigman: Specific binding of a HeLa cell nuclear protein to RNA sequences in the human immunodeficiency virus transactivating region. Proc Natl Acad Sci U S A 86, 4858-4862 (1989) 52. Cordingley, M. G., R. L. LaFemina, P. L. Callahan, J. H. Condra, V. V. Sardana, D. J. Graham, T. M. Nguyen, K. LeGrow, L. Gotlib, A. J. Schlabach and R. J. Colonno: Sequence-specific interaction of Tat protein and Tat peptides with the transactivation-responsive sequence element of human immunodeficiency virus type 1 in vitro. Proc Natl Acad Sci U S A 87, 8985-8989 (1990) 53. Dingwall, C., I. Ernberg, M. J. Gait, S. M. Green, S. Heaphy, J. Karn, A. D. Lowe, M. Singh, M. A. Skinner and R. Valerio: Human immunodeficiency virus 1 tat protein binds trans-activation-responsive region (TAR) RNA in vitro. Proc Natl Acad Sci U S A 86, 6925-6929 (1989) 54. Roy, S., N. T. Parkin, C. Rosen, J. Itovitch and N. Sonenberg: Structural requirements for trans-activation of human immunodeficiency virus type 1 long terminal repeat-directed gene expression by tat: importance of base pairing, loop sequence, and bulges in tat-responsive sequences. J Virol 64, 1402-1406 (1990) 55. Sumner-Smith, M., S. Roy, R. Barnett, L. S. Reid, R. Kuperman, U. Delling and N. Sonenberg: Critical chemical features in trans-acting-responsive RNA are required for interaction with human immunodeficiency virus type 1 tat protein. J Virol 65, 5196-5202 (1991) 56. Bohjanen, P. R., Y. Liu and M. A. Garcia-Blanco: TAR RNA decoys inhibit Tat-activated HIV-1 transcription after pre-initiation complex formation. Nucleic Acids Res 25, 4481-4486 (1997) 57. Herrmann, C. H. and A. R. Rice: Lentivirus Tat proteins specifically associate with a cellular protein kinase, TAK, that hyperphosphorylates the carboxyl-terminal domain of the large subunit of RNA polymerase II: candidate for a tat cofactor. J Virol 69, 1612-1620 (1995) 58. Garcia-Martinez, L. F., G. Mavankal, J. M. Neveu, W. S. Lane, D. Ivanov and R. B. Gaynor: Purification of a Tat-associated kinase reveals a TFIIH complex that modulates HIV-1 transcription. EMBO J 16, 2836-50 (1997) 59. Zhu, Y., T. Pe'ery, J. Peng, Y. Ramanathan, N. Marshall, T. Marshall, B. Amendt, M. B. Mathewa and D. H. Price: Transcription elongation factor P-TEFb is required for HIV-1 Tat transactivation in vitro. Genes Dev 11, 2622-2632 (1997) 60. Cujec, T. P., H. Okamoto, K. Fujinaga, J. Meyer, H. Chamberlin, D. O. Morgan and B. M. Peterlin: The HIV transactivator Tat binds to the CDK-activating kinase that activates the phosphorylation of the carboxy-terminal domain of RNA polymerase II. Genes Dev 11, 2645-2657 (1997) 61. Mancebo, Y. S. H., G. Lee, J. Flygare, J. Tomassini, P. Luu, Y. Zhu, J. Peng, C. Blau, D. Hazuda, D. Price and O. Flores: P-TEFb kinase is required for HIV Tat transcriptional activation in vivo and in vitro. Genes Dev 11, 2633-2644 (1997) 62. Cullen, B. R: Mechanism of action of regulatory proteins encoded by complex retroviruses. Microbiol Rev 56, 375-394 (1992) 63. Battiste, J. L., H. Mao, S. Rao, R. Tan, D. R. Muhandiram, L. E. Kay, A. D. Frankel and J. R. Williamson: Alpha helix-RNA major groove recognition in an HIV-1 Rev peptide-RRE RNA complex. Science 273, 1547-1551 (1996) 64. Daly, T. J., K. S. Cook, G. S. Gray, T. E. Maione and J. R. Rusche: Specific binding of HIV-1 recombinant Rev protein to the Rev-response element in vitro. Nature 342, 816-819 (1989) 65. Malim, M. H., J. Hauber, S.-Y. Le, J. V. Maizel and B. R. Cullen: The HIV-1 rev trans-activator acts through a structured target sequence to activate nuclear export of unspliced viral mRNA. Nature 338, 254-257 (1989) 66. Fischer, U., J. Huber, W. C. Boelens, I. W. Mattaj and R. Lührman: The HIV-1 Rev activations domain is a nuclear export signal that accesses an export pathway used by specific cellular RNAs. Cell 82, 475-483 (1995). 67. Wen, W., J. L. Meinkoth, R. Y. Tsien and S. S. Taylor: Identification of a signal for rapid export of proteins from nucleus. Cell 82, 463-473 (1995) 68. Stade, K., C. S. Ford, C. Guthrie and K. Weis: Exportin 1 (Crm1p) is an essential nuclear export factor. Cell 90, 1041-1050 (1997) 69. Fornerod, M., M. Ohno, M. Yoshida and I. W. Mattaj: CRM1 is an export receptor for leucine-rich nuclear export signals. Cell 90, 1051-1060 (1997) 70. Ullman, K. S., M. A. Powers and D. J. Forbes: Nuclear export receptors: From importin to exportin. Cell 90, 967-970 (1997) 71. Bogerd, H. P., R. A. Fridell, S. Madore and B. R. Cullen: Identification of a novel cellular cofactor for the rev/rex class of retroviral regulatory proteins. Cell 82, 485-494 (1995) 72. Stutz, F., M. Neville and M. Rosbash: Identification of a novel nuclear pore-associated protein as a functional target of the HIV-1 rev protein in yeast. Cell 82, 495-506 (1995) 73. Fritz, C. C., M. L. Zapp and M. R. Green: A human nucleoporin-like protein that specifically interacts with HIV Rev. Nature 376, 530-533 (1995) 74. Kestler, H. W., III, D. J. Ringler, K. Mori, D. L. Panicali, P. K. Sehgal, M. D. Daniel and R. C. Desrosiers: Importance of the nef gene for maintenance of high virus loads and for development of AIDS. Cell 65, 651-662 (1991) 75. Kerkau, T., R. Schmitt-Landgraf, A. Schimpl and E. Wecker: Downregulation of HLA class I antigens in HIV-1-infected cells. AIDS Res Hum Retroviruses 5, 613-620 (1989) 76. Scheppler, J. A., J. K. A. Nicholson, D. C. Swan, A. Ahmed-Ansari and J. S. McDougal: Down-modulation of MHC-I in a CD4+ T cell line, CEM-E5, after HIV-1 infection. J Immunol 143, 2858-2866 (1989) 77. Garcia, J. V. and A. D. Miller: Serine phosphorylation-independent downregulation of cell-surface CD4 by nef. Nature 350, 508-511 (1991) 78. Aiken, C., J. Konner, N. R. Landau, M. E. Lenburg and D. Trono: Nef induces CD4 endocytosis: Requirement for a critical dileucine motif in the membrane-proximal CD4 cytoplasmic domain. Cell 76, 853-864 (1994) 79. Schwartz, O., V. Maréchal, S. Le Gall, F. Lemonnier and J.-M. Heard: Endocytosis of major histocompatibility complex class I molecules is induced by the HIV-1 nef protein. Nature Med 2, 338-342 (1996) 80. Gulizia, R. J., R. G. Collman, J. A. Levy, D. Trono and D. E. Mosier: Deletion of nef slows but does not prevent CD4-positive T-cell depletion in human immunodeficiency virus type 1-infected human-PBL-SCID mice. J Virol 71, 4161-4164 (1997) 81. Debouck, C., T. A. Tomaszek Jr, L. A. Ivanoff and J. Culp: HIV protease. In: HIV. Biochemistry, molecular biology, and drug discovery. Ed: Karn, J., Oxford University Press, Oxford (1995) 82. Chen, B. K., R. T. Gandhi and D. Baltimore: CD4 down-modulation during infection of human T cells with human immunodeficiency virus type 1 involves independent activities of vpu, env and nef. J Virol 70, 6044-6053 (1996) 83. Simon, J. H. M., R. A. M. Fouchier, T. E. Southerling, C. B. Guerra, C. K. Grant and M. H. Malim: The vif and gag proteins of human immunodeficiency virus type 1 colocalize in infected human T cells. J Virol 71, 5259-5267 (1997) 84. Mann, R. and D. Baltimore: Varying the position of a retrovirus packaging sequence results in the encapsidation of both unspliced and spliced RNAs. J Virol 54, 401-407 (1985). 85. Lever, A., H. Gottlinger, W. Haseltine and J. Sodroski. Identification of a sequence required for efficient packaging of human immunodeficiency virus type 1 RNA into virions. J Virol 63, 4085-4087 (1989) 86. Rice, W. G., J. G. Supko, L. Malspeis, R. W. Buckheit, D. Clanton, M. Bu, L. Graham, C. A. Schaeffer, J. A. Turpin, J. Domagala, R. Gogliotti, J. P. Bader, S. M. Halliday, L. Coren, R. C. Sowder, L. O. Arthur and L. E. Henderson: Inhibitors of HIV nucleoprotein Zinc fingers as candidates for the treatment of AIDS. Science 270, 1194-1197 (1995) 87. Caputo, A., M. P. Grossi, C. Rossi, M. Betti, P. C. Marconi, G. Barbanti-Brodano and P. G. Balboni: Inhibition of HIV-1 replication and reactivation from latency by tat transdominant negative mutants in the cysteine rich region. Gene Therapy 3, 235-245 (1996) 88. Green, M., M. Ishino and P. M. Loewenstein: Mutational analysis of HIV-1 Tat minimal domain peptides: Identification of trans-dominant mutants that suppress HIV-LTR-driven gene expression. Cell 58, 215-223 (1989) 89. Pearson, L., J. Garcia, F. Wu, N. Modesti, J. Nelson and R. Gaynor: A transdominant tat mutant that inhibits tat-induced gene expression from the human immunodeficiency virus long terminal repeat. Proc Natl Acad Sci USA 87, 5079-5083 (1990) 90. Modesti, N., J. Garcia, C. Debouck, M. Peterlin and R. Gaynor: Trans-dominant Tat mutants with alterations in the basic domain inhibit HIV-1 gene expression. New Biol 3, 759-768 (1991) 91. Rice, A. P. and F. Carlotti: Mutational analysis of the conserved cysteine-rich region of the human immunodeficiency virus type 1 Tat protein. J Virol 64, 1864-1868 (1990) 92. Madore, S. J. and B. R. Cullen: Genetic analysis of the cofactor requirement for human immunodeficiency virus type 1 Tat function. J Virol 67, 3703-3711 (1993) 93. Orsini, M. J. and C. M. Debouck: Inhibition of human immunodeficiency virus type 1 and type 2 Tat function by transdominant Tat protein localized to both the nucleus and the cytoplasm. J Virol 70, 8055-8063 (1996) 94. Kamine, J., P. Loewenstein and M. Green: Mapping of HIV-1 Tat protein sequences required for binding to Tar RNA. Virology 182, 570-577 (1991) 95. Mhashilkar, , A. M., J. Bagley, S. Y. Chen, A. M. Szilvay, D. G. Helland and W. A. Marasco: Inhibition of HIV-1 Tat-mediated LTR transactivation and HIV-1 infection by anti-Tat single chain intrabodies. EMBO J 14, 1542-1551 (1995) 96. Biasolo, M. A., A. Radelli, L. Del Pup, E. Franchin, C. De Giuli-Morghen and G. Palu: A new antisense tRNA construct for the genetic tratment of human immunodeficiency virus type 1 infection. J Virol 70, 2154-2161 (1996) 97. Lo, K. M. S., M. A. Biasolo, G. Dehni, G. Palu and W. A. Haseltine: Inhibition of replication of HIV-1 by retroviral vectors expressing tat-antisense and anti-tat ribozyme RNA. Virology 190, 176-183 (1992). 98. Sun, L. Q., L. Wang, W. L. Gerlach and G. Symonds: Target sequence-specific inhibition of HIV-1 replication by ribozymes directed to tat RNA. Nucleic Acids Res 23, 2909-2913 (1995) 99. Chatterjee, S., P. R. Johnson and K. K. Wong Jr: Dual-target inhibition of HIV-1 in vitro by means of an adeno-associated virus antisense vector. Science 258, 1485-1488 (1992) 100. Marciniak, R. A., B. J. Calnan, A. D. Frankel and P. A. Sharp: HIV-1 Tat protein trans-activates transcription in vitro. Cell 63, 791-802 (1990) 101. Bohjanen, P. R., R. A. Colvin, M. Puttarju, M. D. Been and M. A. Garcia-Blanco: A small circular TAR RNA decoy specifically inhibits Tat-activated HIV-1 transcription. Nucleic Acids Res 24, 3733-3738 (1996) 102. Sullenger, B. A., H. F. Gallardo, G. E. Ungers and E. Gilboa: Analysis of trans-acting response decoy RNA-mediated inhibition of human immuodeficiency virus type 1 transactivation. J Virol 65, 6811-6816 (1991) 103. Sullenger, B. A., T. C. Lee, C. A. Smith, G. E. Ungers and E. Gilboa: Expression of chimeric tRNA-driven antisense transcripts renders NIH 3T3 cells highly resistant to Moloney murine leukemia virus replication. Mol Cell Biol 10, 6512-6523 (1990) 104. Lee, S. W., H. F. Gallardo, C. Smith and E. Gilboa: Inhibition of HIV-1 in CEM cells by a potent TAR decoy. Gene Ther 2, 377-384 (1995) 105. Lisziewicz, J., J. Rappaport and R. Dhar: Tat-regulated production of multimerized TAR RNA inhibits HIV-1 gene expression. New Biol 3, 82-89 (1991) 106. Lisziewicz, J., D. Sun, J. Smythe, P. Lusso, F. Lori, A. Louie, P. Markham, J. Rossi, M. Reitz and R. C. Gallo: Inhibition of human immunodeficiency virus type 1 replication by regulated expression of a polymeric Tat activation response RNA decoy as a strategy for gene therapy in AIDS. Proc Natl Acad Sci U S A 90, 8000-8004 (1993) 107. Lori, F., J. Lisziewicz, J. Smythe, A. Cara, T. A. Bunnag, D. Curiel and R. C. Gallo: Rapid protection against human immunodeficiency virus type 1 (HIV-1) replication mediated by high efficiency non-retroviral delivery of genes interfering with HIV-1 tat and gag. Gene Ther 1, 27-31 (1994) 108. Chang, H. K., R. Gendelman, J. Lisziewicz, R. C. Gallo and B. Ensoli: Block of HIV-1 infection by a combination of antisense tat RNA and TAR decoys: a strategy for control of HIV-1. Gene Ther 1, 208-216 (1994) 109. Lisziewicz, J., D. Sun, B. Trapnell, M. Thomson, H. K. Chang, B. Ensoli and B. Peng: An autoregulated dual-function antitat gene for human immunodeficiency virus type 1 gene therapy. J Virol 69, 206-212 (1995) 110. Lisziewicz, J., D. Sun, R. C. Gallo, B. Ensoli and F. Lori: Efficacy of antitat gene therapy in the presence of high multiplicity infection and inflammatory cytokines. Hum Gene Ther 7, 2209-16 (1996) 111. Lisziewicz, J., D. Sun, A. Lisziewicz and R. C. Gallo. Antitat gene therapy: a candidate for late-stage AIDS patients. Gene Ther 2, 218-222 (1995) 112. Rosenzweig, M., D. F. Marks, D. Hempel, J. Lisziewicz and R. P. Johnson: Transduction of CD34+ hematopoietic progenitor cells with an antitat gene protects T-cell and macrophage progeny from AIDS virus infection. J Virol 71, 2740-2746 (1997) 113. Malim, M. H., S. Bohnlein, J. Hauber and B. R. Cullen: Functional dissection of the HIV-1 Rev trans-activator - derivation of a trans-dominant repressor of Rev function. Cell 58, 205-214 (1989) 114. Escaich, S., C. Kalfglou, I. Plavec, S. Kaushal, J. D. Mosca and E. Bohnlein: RevM10-mediated inhibition of HIV-1 replication in chronically infected T cells. Hum Gene Ther 6, 625-634 (1995) 115. Liu, J., C. Wofferdin, Z. Y. Yang and G. J. Nabel: Regulated expression of a dominant negative form of rev improves resistance to HIV replication in T cells. Gene Ther 1, 32-37 (1994) 116. Malim, M. H., W. W. Freimuth, J. Liu, T. J. Boyle, H. K. Lyerly, B. R. Cullen and G. J. Nabel: Stable expression of transdominant Rev protein in human T cells inhibits human immunodeficiency virus replication. J Exp Med 176, 1197-1201 (1992) 117. Ragheb, J. A., P. Bressler, M. Daucher, L. Chiang, M. K. L. Chuah, T. Vandendriessche and R. A. Morgan: Analysis of trans-dominant mutants of the HIV type 1 rev protein for their ability to inhibit rev function, HIV type 1 replication, and their use as anti-HIV gene therapeutics. AIDS Res Hum Retroviruses 11, 1343-1353 (1995) 118. Wofferdin, C., Z. Y. Yang, Udaykumar, L. Xu, N. S. Yang, M. J. Sheeny and G. J. Nabel: Nonviral and viral delivery of a human immunodeficiency virus protective gene into primary human T cells. Proc Natl. Acad. Sci USA 91, 11581-11585 (1994) 119. Wofferdin, C., U. Ranga, Z. Y. Yang, L. Xu and G. J. Nabel: Expression of a protective gene prolongs survival of T cells in human immunodeficiency virus-infected patients. Proc Natl Acad Sci USA 93, 2889-2894 (1996) 120. Nabel, G. J., B. A. Fox, L. Post, C. B. Thompson and C. Wofferdin: A molecular genetic intervention for AIDS-Effects of a transdominant negative form of rev. Hum Gene Ther 5, 79-92 (1994) 121. Plavec, I., M. Agarwal, K. E. Ho, M. Pineda, J. Auten, J. Baker, H. Matsuzaki, S. Escaich, M. Bonyhadi and E. Böhnlein: High transdominant RevM10 protein levels are required to inhibit HIV-1 replication in cell lines and primary T cells: implication for gene therapy of AIDS. Gene Ther 4, 128-139 (1997) 122. Qian, X., Z. Chen, J. Zhang, A. B. Rabson and R. M. Krug: New approach for inhibiting REV function and HIV-1 production using the influenza virus NS1 protein. Proc Natl Acad Sci USA 93, 8873-8877 (1996) 123. Li, G., J. Lisziewicz, D. Sun, G. Zon, S. Daefler, F. Wong-Staal, R. C. Gallo and M. E. Klotman: Inhibition of Rev activity and human immunodeficiency virus type 1 replication by antisense oligodeoxynucleotide phosphothioate analogs directed against the Rev-response element. J Virol 67, 6882-6888 (1993) 124. Lisziewicz, J., D. Sun, M. Klotman, S. Agrawal, P. Zamecnik and R. Gallo: Specific inhibition of human immunodeficiency virus type 1 replication by antisense oligonucleotides: An in vitro model for treatment. Proc Natl Acad Sci USA 89, 11209-11213 (1992) 125. Sczakiel, G., M. Oppenlander, K. Rittner and M. Pawlita: Tat- and Rev-directed antisense RNA expression inhibits and abolishes replication of human immunodeficiency virus type 1: a temporal analysis. J Virol 66, 5576-5581 (1992) 126. Bahner, I., K. Kearns, Q. Hao, E. M. Smogorzewska and D. B. Kohn: Transduction of human CD34+ hematopoietic progenitor cells by a retroviral vector expressing an RRE decoy inhibits human immunodeficiency virus type 1 replication in myelomonocytic cells produced in long term culture. J Virol 70, 4352-4360 (1996) 127. Lee, T. C., B. A. Sullenger, H. F. Gallardo, G. E. Ungers and E. Gilboa: Overexpression of RRE-derived sequences inhibits HIV-1 replication in CEM cells. New Biol 4, 66-74 (1992) 128. Lee, S. W., H. F. Gallardo, E. Gilboa and C. Smith: Inhibition of Human Immunodeficiency Virus Type 1 in human T cells by a potent rev response element decoy consisting of the 13-nucleotide minimal rev-binding domain. J Virol 68, 8254-8264 (1994) 129. Smith, C., S.-W. Lee, E. Wong, H. Gallardo, K. Page, O. Gaspar, J. Lebkowski and E. Gilboa: Transient protection of human T-cells from human immunodeficiency virus type 1 infection by transduction with adeno-associated viral vectors which express RNA decoys. Antiviral Res 32, 99-115 (1996) 130. Good, P. D., A. J. Krikos, S. X. L. Li, E. Bertrand, N. S. Lee, L. Giver, A. Ellinton, J. A. Zaia, J. J. Rossi and D. R. Engelke: Expression of small, therapeutic RNAs in human cell nuclei. Gene Ther 4, 45-54 (1997) 131. Gottfredsson, M., T. Gentry, K. Phillips, S. Hull, E. Gilboa and C. Smith: Suppression of HIV-1 replication in human T cells transduced with an RNA decoy mimicking the rev binding domain of RRE (abstr. I15). In: Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology (1996) 132. Zhou, C., I. C. Bahner, G. P. Larson, J. A. Zaia, J. J. Rossi and D. B. Kohn: Inhibition of HIV-1 in human T-lymphocytes by retrovirally transduced anti-tat and rev hammerhead ribozymes. Gene 149, 33-39 (1994) 133. Duan, L., H. Zhang, J. W. Oakes, O. Bagasra and R. J. Pomerantz: Molecular and virological effects of intracellular anti-Rev single-chain variable fragments on the expression of various human immunodeficency virus-1 strains. Hum Gene Ther 5, 1315-1324 (1994) 134. Duan, L., O. Bagasra, M. A. Laughlin, J. W. Oakes and R. J. Pomerantz: Potent inhibition of human immunodeficiency virus type 1 replication by an intracellular anti-Rev single-chain antibody. Proc Natl Acad Sci USA 91, 5075-5079 (1994) 135. Wu, Y., L. Duan, M. Zhu, B. Hu, S. Kubota, O. Bagasra and R. J. Pomerantz: Binding of intracellular anti-rev single chain variable fragments to different epitopes of human immunodeficiency virus type 1 rev: Variations in viral inhibition. J Virol 70, 3290-3297 (1996) 136. Kubota, S., L. Duan, R. A. Furuta, M. Hatanaka and R. J. Pomerantz: Nuclear preservation and cytoplasmic degradation of human immunodeficiency virus type 1 Rev protein. J Virol 70, 1282-1287 (1996) 137. Bonyhadi, M. L., K. Moss, A. Voytovich, J. Auten, C. Kalfoglou, I. Plavec, S. Forestell, L. Su, E. Böhnlein and H. Kaneshima: RevM10-expressing T cells derived in vivo from transduced human hematopoietic stem-progenitor cells inhibit human immunodeficiency virus replication. J Virol 71, 4707-4716 (1997) 138. Inouye, R. T., B. Du, D. Boldt-Houle, A. Ferrante, I.-W. Park, S. M. Hammer, L. Duan, J. E. Groopman, R. J. Pomerantz and E. F. Terwilliger: Potent inhibition of human immunodeficiency virus type 1 in primary T cells and alveolar macrophages by a combination anti-Rev strategy delivered in an adeno-associated virus vector. J Virol 71, 4071-4078 (1997) 139. Yamada, O., G. Kraus, M. C. Leavitt, M. Yu and F. Wong-Staal: Activity and cleavage site specificity of an anti-HIV-1 hairpin ribozyme in human T cells. Virology 205, 121-126 (1994) 140. Deacon, N. J., A. Tsykin, A. Solomon, K. Smith, M. Ludford-Menting, D. J. Hooker, D. A. McPhee, A. L. Greenway, A. Ellett, C. Chatfield, V. A. Lawson, S. Crowe, A. Maerz, S. Sonsa, J. Learmont, J. S. Sullivan, A. Cunningham, D. Dwyer, D. Dowton and J. Mills: Genomic structure of an attenuated quasi species of HIV-1 from a blood transfusion donor and recipients. Science 270, 988-991 (1995) 141. Larsson, S., G. Hotchkiss, J. Su, T. Kebede, M. Andäng, T. Nyholm, B. Johansson, A. Sönnerborg, A. Vahlne, S. Britton and L. Ährlund-Richter: A novel ribozyme target site located in the HIV-1 Nef open reading frame. Virology 219, 161-169 (1996) 142. Yu, M., E. Poeschla, O. Yamada, P. Degrandis, M. C. Leavitt, M. Heusch, J. K. Yees, F. Wong-Staal and A. Hampel: In vitro and in vivo characterization of a second functional hairpin ribozyme against HIV-1. Virology 206, 381-386 (1995) 143. Maciejewski, J. P., F. F. Weichold, Y. N. S, A. Cara, D. Zella, M. S. Reitz Jr and R. C. Gallo: Intracellular expression of antibody fragments directed against HIV reverse transcriptase prevents HIV infection in vitro. Nature Med 1, 667-673 (1995) 144. Bordier, B., C. Helene, P. J. Barr, S. Litvak and L. Sarih-Cottin: In vitro effect of antisense oligonucleotides on human immunodeficiency virus type 1 reverse transcription. Nucleic Acids Res 20, 5999-6006 (1992) 145. Craigie, R., A. B. Hickman and A. Engelman: Integrase. In: HIV. Biochemistry, molecular biology, and drug discovery. Ed: Karn, J., Oxford University Press, Oxford 2, 53-71 (1995). 146. Sioud, M. and K. Drlica: Prevention of human immunodeficiency virus type 1 integrase expression in Escherichia coli by a ribozyme. Proc Natl Acad Sci USA 88, 7303-7307 (1991) 147. Levy-Mintz, P., L. Duan, H. Zhang, B. Hu, G. Dornadula, M. Zhu, J. Kulkosky, D. Bizub-Bender, A. M. Skalka and R. J. Pomerantz: Intracellular expression of single-chain variable fragments to inhibit early stages of the viral life cycle by targeting human immunodeficiency virus type 1 integrase. J Virol 70, 8821-8832 (1996) 148. Babé, L. M., J. Rosé and C. S. Craik: Trans-dominant inhibitory immunodeficiency virus type 1 protease monomers prevent protease activation and virion maturation. Proc Natl Acad Sci USA 92, 10069-10073 (1995) 149. Junker, U., S. Escaich, I. Plavec, J. Baker, F. McPhee, J. R. Rosé, C. S. Craik and E. Böhnlein: Intracellular expression of human immunodeficiency virus type 1 (HIV-1) protease variants inhibits replication of wild-type and protease inhibitor-resistant HIV-1 strains in human T-cell lines. J Virol 70, 7765-7772 (1996) 150. Serio, D., T. A. Rizvi, M. Cartas, V. S. Kalyanaraman, I. T. Weber, H. Koprowski and A. Srinivasan: Dvelopment of a novel anti-HIV-1 agent from within: Effect of chimeric Vpr-containing protease cleavage site residues on virus replication. Proc Natl Acad Sci USA 94, 3346-3351 (1997) 151. Trono, D., M. B. Feinberg and D. Baltimore: HIV- gag mutants can dominantly interfere with the replication of the wild-type virus. Cell 59, 113-120 (1989) 152. Sczakiel, G., M. Pawlita and A. Kleinheinz: Specific inhibition of human immunodeficiency virus type 1 replication by RNA transcribed in sense and antisense from the 5'-leader/gag region. Biochem Biophys Res Comm 169, 643-651 (1990) 153. Sczakiel, G. and M. Pawlita: Inhibition of human immunodeficiency virus type 1 replication in human T cells stably expressing antisense RNA. J Virol 65, 468-472 (1991) 154. Veres, G., S. Escaich, J. Baker, C. Barske, C. Kalfoglou, H. Ilves, H. Kaneshima and E. Böhnlein: Intracellular expression of RNA transcripts complementary to the human immunodeficiency virus type 1 gag gene inhibits viral replication in human CD4+ lymphocytes. J Virol 70, 8792-8800 (1996) 155. Sarver, N., E. M. Cantin, P. S. Chang, J. A. Zaia, P. A. Ladne, D. A. Stephens and J. J. Rossi: Ribozymes as potential anti-HIV-1 therapeutic agents. Science 247, 1222-1225 (1990) 156. Schumann, G., L. Qin, A. Rein, G. Natsoulis and J. D. Boeke: Therapeutic effect of gag-nuclease fusion protein on retrovirus-infected cell cultures. J Virol 70, 4329-4337 (1996) 157. Schumann, G., K. Cannon, W.-P. Ma, R. J. Crouch and J. D. Boeke: Antiretroviral effect of a gag-RNase HI fusion gene. Gene Ther 4, 593-599 (1997) 158. Mebatsion, T., S. Finke, F. Weiland and K.-K. Conzelman: A CXCR4/CD4 psudotype rhabdovirus that selectively infects HIV-1 envelope protein-expressing cells. Cell 90, 841-847 (1997) 159. Schnell, M. J., J. E. Johnson, L. Buonocore and J. K. Rose: Construction of a novel virus that targets HIV-1-infected cells and controls HIV-1 infection. Cell 90, 849-857 (1997) 160. Schnierle, B. S., J. Stitz, V. Bosch, F. Nocken, H. Merget-Millitzer, M. Engelstädter, R. Kurth, B. Groner and K. Cichutek: Pseudotyping of murine leukemia virus with the envelope glycoproteins of HIV generates a retroviral vector with specificity of infection for CD4-expressing cells. Proc Natl Acad Sci USA 94, 8640-8645 (1997) 161. Marasco, W. A., W. A. Haseltine and S. Chen: Design, intracellular expression, and activity of a human anti-human immunodeficiency virus type 1 gp120 single-chain antibody. Proc Natl Acad Sci USA 90, 7889-7893 (1993) 162. Chen, C., -J., A. C. Banerjea, G. G. Harmison, K. Haglund and M. Schubert: Multitarget-ribozyme directed to cleave at up to nine highly conserved HIV-1 env RNA regions inhibits HIV-1 replication - potential effectiveness against most presently sequenced HIV-1 isolates. Nucleic Acids Res 20, 4581-4589 (1992) 163. Wu, X., H. Liu, H. Xiao, J. Kim, P. Seshaiah, G. Natsoulis, J. D. Boeke, B. H. Hahn and J. C. Kappes: Targeting foreign proteins to human immunodeficiency virus particles via fusion with vpr and vpx. J Virol 69, 3389-3398 (1995) 164. Ojwang, J. O., A. Hampel, D. J. Looney, F. Wong-Staal and J. Rappaport: Inhibition of human immunodeficiency virus type 1 expression by a hairpin ribozyme. Proc Natl Acad Sci USA 89, 10802-10806 (1992) 165. Dropulic, B., N. H. Lin, M. A. Martin and K.-T. Jeang: Functional characterization of a U5 ribozyme: Intracellular suppression of human immunodeficiency virus type 1 expression. J Virol 66, 1432-1441 (1992) 166. Yamada, O., M. Yu, J. K. Yee, G. Kraus, D. Looney and F. Wong-Staal: Intracellular immunization of human T cells with a hairpin ribozyme against human immunodeficiency virus type 1. Gene Ther 1, 38-45 (1994) 167. Yu, M., J. Ojwang, O. Yamada, A. Hampel, J. Rapapport, D. Looney and F. Wong-Staal. A hairpin ribozyme inhibits expression of diverse strains of human immunodeficiency virus Type 1. Proc Natl Acad Sci USA 90, 6340-6344 (1993) 168. Weerasinghe, M., S. E. Liem, S. Asad, S. E. Read and S. Joshi: Resistance to human immunodeficiency virus type 1 (HIV-1) infection in human CD4+ lymphocyte-derived cell lines conferred by using retroviral vectors expressing an HIV-1 RNA-specific ribozyme. J Virol 65, 5531-5534 (1991) 169. Leavitt, M. C., M. Yu, O. Yamada, G. Kraus, D. Looney, E. Poeschla and F. Wong-Staal: Transfer of an anti-HIV-1 ribozyme gene into primary human lymphocytes. Hum Gene Ther 5, 1115-1120 (1994) 170. Yu, M., M. C. Leavitt, M. Maruyama, O. Yamada, D. Young, A. D. Ho and F. Wong-Staal: Intracellular immunization of human fetal cord blood stem/progenitor cells with a ribozyme against human immunodeficiency virus type 1. Proc Natl Acad Sci USA 92, 669-703 (1995) 171. Sun, L. -Q., D. Warrilow, L. Wang, C. Witherington, J. Macpherson and G. Symonds: Ribozyme-mediated suppression of Moloney murine leukemia virus and human immunodeficiency virus type I replication in permissive cell lines. Proc Natl Acad Sci USA 91, 9715-9719 (1994) 172. Hamouda, T., R. McPhee, S.-C. Hsia, G. S. Read, T. C. Holland and S. R. King: Inhibition of human immunodeficiency virus replication by the herpes simplex virion shutoff protein. J Virol 71, 5521-5527 (1997) 173. Caruso, M. and D. Klatzmann: Selective killing of CD4+ cells harboring a human immunodeficiency virus-inducible suicide gene prevents viral spread in an infected population. Proc Natl Acad Sci USA 89, 182-186 (1992) 174. Brady, H. J. M., C. G. Miles, D. J. Pennington and E. A. Dzierzak: Specific ablation of human immunodeficiency virus Tat-expressing cells by conditionally toxic retroviruses. Proc Natl Acad Sci USA 91, 356-369 (1994) 175. Venkatesh, L. K., M. Q. Arens, T. Subramanian and G. Chinnadurai: Selective inhibition of toxicity to human cells expressing human immunodeficiency virus type 1 Tat by a conditionally cytotoxic adenovirus vector. Proc Natl Acad Sci USA 87, 8746-8750 (1990) 176. Harrison, G. S., C. J. Long, T. J. Curiel, F. Maxwell and I. H. Maxwell: Inhibition of human immunodeficiency virus-1 production resulting from transduction with a retrovirus containing an HIV-regulated diphteria toxin A chain gene. Hum Gene Ther 3, 461-469 (1992) 177. Harrison, G. S., C. J. Long, F. Maxwell, L. M. Glode and I. H. Maxwell: Inhibition of HIV production in cells containing an integrated, HIV-regulated diphteria toxin A chain gene. AIDS Res Hum Retroviruses 8, 39-45 (1992) 178. Winters, M. A. and T. C. Merigan: Continuous presence of CD4-PE40 is required for antiviral activity against single-passage HIV isolates and infected peripheral blood mononuclear cells. AIDS Res Hum Retroviruses 9, 1091-1096 (1993) 179. Mhashilkar, A. M., D. K. Biswas, J. LaVecchio, A. B. Pardee and W. A. Marasco: Inhibition of human immunodeficiency virus type 1 replication in vitro by a novel combination of anti-Tat single-chain intrabodies and NF-kB antagonists. J Virol 71, 6486-6494 (1997) 180. Yuyama, N., J. Ohkawa, T. Koguma, M. Shirai and K. Taira: A multifunctional expression vector for an anti-HIV-1 ribozyme that produces a 5'- and 3'-trimmed trans-acting ribozyme, targeted against HIV-1 RNA, and cis-acting ribozymes that are designed to bind to and thereby sequester trans-activator proteins such as Tat and Rev. Nucleic Acids Res 22, 5060-5067 (1994) 181. Lisziewics, J., D. Sun, J. Smythe, P. Lusso, F. Lori, A. Louie, P. Markham, J. Rossi, M. Reitz and R. C. Gallo: Inhibition of human immunodeficiency virus type 1 replication by regulated expression of polymeric Tat activation response RNA decoy as a strategy for gene therapy in AIDS. Proc Natl Acad Sci USA 90, 8000-8004 (1993) 182. Yamada, O., G. Kraus, L. Luznik, M. Yu and F. Wong-Staal: A chimeric human immunodeficiency virus type 1 (HIV-1) minimal rev response element-ribozyme molecule exhibits dual antiviral function and inhibits cell-cell transmission of HIV-1. J Virol 70, 1596-1601 (1996) 183. Gervaix, A., X. Li, G. Kraus and F. Wong-Staal: Multigene antiviral vectors inhibit diverse human immunodeficiency virus type 1 clades. J Virol 71, 3048-3053 (1997) 184. Aguilar-Cordova, E. C., J. Chinen, L. Donehower, J. W. Harper, J. S. Butel and J. W. Belmont: Inhibition of HIV-1 by a double transdominant fusion gene. Gene Ther 2, 181-186 (1995) 185. Chinen, J., E. Aguilar-Cordova, D. Ng-Tang, D. E. Lewis and J. W. Belmont: Protection of primary human T cells from HIV infection by Trev: A transdominant fusion gene. Hum Gene Ther 8, 861-868 (1997) 186. Ulich, C., D. Harrich, P. Estes and R. B. Gaynor: Inhibition of Human Immunodeficiency Virus Type 1 replication is enhanced by a combination of transdominant tat and rev proteins. J Virol 70, 4871-4876 (1996). 187. Ramezani, A., S. F. Ding and S. Joshi: Inhibition of HIV-1 replication by retroviral vectors expressing monomeric and multimeric hammerhead ribozymes. Gene Ther 4, 861-867 (1997) 188. Ohkawa, J., N. Yuyama, Y. Takebe, S. Nishikawa and K. Taira: Importance of independence in ribozyme reactions: Kinetic behavior of trimmed and simply connected ribozymes with potential activity against human immunodeficiency virus. Proc Natl Acad Sci USA 90, 11302-11306 (1993) 189. Liu, D., J. Donegan, G. Nuovo, D. Mitra and J. Laurence: Stable human immunodeficiency virus type 1 (HIV-1) resistance in transformed CD4+ monocytic cells treated with multitargeting HIV-1 antisense sequences incorporated into U1 snRNA. J Virol 71, 4079-4085 (1997) 190. Duan, L., M. Zhu, I. Ozaki, H. Zhang, D. L. Wei and R. J. Pomerantz: Intracellular inhibition of HIV-1 replication using a dual protein- and RNA-based strategy. Gene Ther 4, 533-543 (1997) 191. Dean, M., M. Carrington, C. Winkler, G. A. Huttley, M. W. Smith, R. Allikmets, J. J. Goedert, S. P. Buchbinder, E. Vittinghoff, E. Gomperts, S. Donfield, D. Vlahov, R. Kaslow, A. Saah, C. Rinaldo, R. Detels and S. J. O'Brien: Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Science 273, 1856-1862 (1996) 192. Walker, R. E: A phase I/II pilot study of the safety of the adoptive transfer of syngeneic gene-modified cytotoxic T lymphocytes in HIV-infected identical twins. Hum Gene Ther 7, 367-400 (1996) 193. Sanhadji, K., P. Leissner, R. Firouzi, F. Pelloquin, L. Kehrli, M. Marigliano, V. Calenda, M. Ottmann, J. C. Tardy, M. Mehtali and J. L. Touraine: Experimental gene therapy: the transfer of Tat-inducible interferon genes protects human cells against HIV-1 challenge in vitro and in vivo in severe combined immunodeficient mice. AIDS 11, 977-86 (1997) 194. Hammer, S. M., K. E. Squires, M. D. Hughes, J. M. Grimes, L. M. Demeter, J. S. Currier, J. J. Eron, Jr., J. E. Feinberg, H. H. Balfour, Jr., L. R. Deyton, J. A. Chodakewitz and M. A. Fischl: A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med 337, 725-33 (1997)

[Frontiers in Bioscience 2, d619-634, December 15, 1997]
Reprints
PubMed
CAVEAT LECTOR

HUMAN IMMUNODEFICIENCY VIRUS TYPE I AS A TARGET FOR GENE THERAPY

Magnús Gottfredsson and Paul R. Bohjanen

Division of Infectious Diseases and International Health, Department of Medicine, Duke University Medical Center, Durham, NC 27710

Received 11/17/97 Accepted 11/24/97

8. REFERENCES

1. Mertens, T. E. and D. Low-Beer: HIV and AIDS: where is the epidemic going? Bull World Health Organ 74, 121-9 (1996)

2. Cavert, W., D. W. Notermans, K. Gebhard, K. Henry, Z.-Q. Zhang, R. Mills, H. McDade, J. Goudsmit, S. A. Danner and A. T. Haase: Kinetics of response in lymphoid tissues to antiretroviral therapy of HIV-1 infection. Science 276, 960-964 (1997)

3. Gulick, R.M., J. W. Mellors, D. Havlir, J. J. Eron, C. Gonzalez, D. McMahon, D. D. Richman, F. T. Valentine, L. Jonas, A. Meibohm, E. A. Emini and J. A. Chodakewitz: Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 337, 734-9 (1997)

4. Ho, D. D., A. U. Neumann, A. S. Perelson, W. Chen, J. M. Leonard and M. Markowitz: Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 373, 123-126 (1995)

5. Wei, X., S. K. Ghosh, M. E. Taylor, V. A. Johnson, E. A. Emini, P. Deutsch, J. D. Lifson, S. Bonhoeffer, M. A. Nowak, B. H. Hahn, M. S. Saag and G. M. Shaw: Viral dynamics in human immunodeficiency virus type 1 infection. Nature 373, 117-122 (1995)

6. Maddon, P.J., A. G. Dalgleish, J. S. McDougal, P. R. Clapham, R. A. Weiss and R. Axel: The T4 gene encodes the AIDS virus receptor and is expressed in the immune system and the brain. Cell 47, 333-348 (1986)

7. Dalgleish, A. G., P. C. L. Beverley, P. R. Clapham, D. H. Crawford, M. F. Greaves and R. A. Weiss: The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus. Nature 312, 763-767 (1984)

8. Klatzman, D., E. Champagne, S. Chamaret, J. Gruest, S. Guetard, T. Hercend, J.-C. Gluckman and L. Montagnier: T lymphocyte T4 molecule behaves as the receptor for human retrovirus LAV. Nature 312, 767-768 (1984)

9. Alkhatib, G., C. Combardiere, C. C. Broder, Y. Feng, P. E. Kennedy, P. M. Murphy and E. A. Berger: CC CKR5: A RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1. Science 272, 1955-1958 (1996)

10. Choe, H., M. Farzan, Y. Sun, N. Sullivan, B. Rollins, P. D. Ponath, L. Wu, C. R. Mackay, G. LaRosa, W. Newman, N. Gerard, C. Gerard and J. Sodorski: The ß-Chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. Cell 85, 1135-1148 (1996)

11. Deng, H., R. Liu, W. Ellmeier, S. Choe, D. Unutmaz, M. Burkhart, P. Marzio, S. Marmon, R. E. Sutton, C. M. Hill, C. B. Davis, P. S. C, T. J. Schall, D. R. Littman and N. R. Landau: Identification of a major co-receptor for primary isolates of HIV-1. Nature 381, 661-666 (1996)

12. Doranz, B. J., J. Rucker, Y. Yi, R. J. Smyth, M. Samson, S. C. Peiper, M. Parmentier, R. G. Collman and R. W. Doms: A dual-tropic primary HIV-1 isolate that uses Fusin and the ß-Chemokine receptors CKR-5, CKR-3, and CKR-2b as Fusion cofactors. Cell 85, 1149-1158 (1996)

13. Dragic, T., V. Litwin, G. P. Allaway, S. R. Martin, Y. Huang, K. A. Nagashima, C. Cayanan, P. J. Maddon, R. A. Koup, J. P. Moore and W. A. Paxton: HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature 381, 667-673 (1996)

14. Feng, Y., C. C. Broder, P. E. Kennedy and E. A. Berger: HIV-1 entry cofactor: Functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science 272, 872-877 (1996)

15. Berson, J. F., D. Long, B. J. Dorantz, J. Rucker, F. R. Jirik and R. W. Doms: A seven transmembrane domain receptor involved in fusion and entry of T-cell-tropic human immunodeficiency virus type 1 strains. J Virol 70, 6288-6295 (1996)

16. Schuitemaker, H., M. Koot, N. A. Koostra, W. Dercksen, R. E. Y. De Goude, R. P. Van Steenwijk, J. M. A. Lange, J. K. M. Eeftink Schattenkerk, F. Miedema and M. Tersmette: Biological phenotype of Human Immunodeficiency Virus Type 1 clones at different stages of infection: Progression of disease is associated with a shift from monocytotropic to T-cell tropic virus populations. J Virol 66, 1354-1360 (1992)

17. Connor, R. I. and D. D. Ho: Human Immunodeficiency Virus Type 1 variants with increased replicative capacity develop during the asymptomatic stage before disease progression. J Virol 68, 4400-4408 (1994)

18. Zhu, T., H. Mo, N. Wang, D. S. Nam, Y. Cao, R. A. Koup and D. D. Ho: Genotypic and phenotypic characterization of HIV-1 in patients with primary infection. Science 261, 1179-1181 (1993)

19. Trono, D: HIV accessory proteins: Leading roles for the supporting cast. Cell 82, 189-192 (1995)

20. Miller, R. H., S. R. Turk, R. J. Black, S. Bridges and N. Sarver: Conference summary: Novel HIV therapies - from discovery to clinical proof of concept. AIDS Res Hum Retroviruses 12, 859-865 (1996)

21. Heinzinger, N. K., M. I. Bukrinsky, S. A. Haggerty, A. M. Ragland, V. Kewalramani, M.-A. Lee, H. E. Gendelman, L. Ratner, M. Stevenson and M. Emerman: The Vpr protein of human immunodeficiency virus type 1 influences nuclear localization of viral nucleic acids in nondividing host cells. Proc Natl Acad Sci USA 91, 7311-7315 (1994)

22. Miller, R. H. and N. Sarver: HIV accessory proteins as therapeutic targets. Nature Med 4, 389-394 (1997)

23. Karn, J: An introduction to the growth cycle of human immunodeficiency virus. In: HIV. Biochemistry, molecular biology, and drug discovery. Ed: Karn, J., Oxford University Press, Oxford (1995)

24. Farnet, C. M. and F. D. Bushman: HIV-1 cDNA integration: Requirement of HMG I(Y) protein for function of preintegration complexes in vitro. Cell 88, 483-492 (1997)

25. Buchschacher, G.L., Jr: Molecular targets of gene transfer therapy for HIV infection. JAMA 269, 2880-2886 (1993)

26. Jones, K. A. and B. M. Peterlin: Control of RNA initiation and elongation at the HIV-1 promoter. Annu Rev Biochem 1994. 63, 717-743 (1994)

27. Karn, J., M. J. Churcher, K. Rittner, N. J. Keen and M. J. Gait: Control of transcriptional elongation by the human immunodeficiency virus Tat protein. In: Eukaryotic Gene Transcription. Ed: Goodbourn, S., Oxford University Press, Oxford (1996)

28. Arya, S. K., C. Guo, S. F. Josephs and F. Wong-Staal: Trans-activator gene of human T-lymphotropic virus typre III (HTLV-III). Science 229, 69-73 (1985)

29. Cullen, B. R: Trans-activation of human immunodeficiency virus occurs via a bimodal mechanism. Cell 46, 973-982 (1986)

30. Feng, S. and E. C. Holland: HIV-1 tat trans-activation requires the loop sequence within tar. Nature 334, 165-167 (1988)

31. Kao, S. Y., A. F. Calman, P. A. Luciw and B. M. Peterlin: Anti-termination of transcription within the long terminal repeat of HIV-1 by tat gene product. Nature 330, 489-493 (1987)

32. Keen, N. J., M. J. Gait and J. Karn: Human immunodeficiency virus type-1 Tat is an integral component of the activated transcription-elongation complex. Proc Natl Acad Sci U S A 93, 2505-2510 (1996)

33. Ratnasabapathy, A. R., M. Sheldon, L. Johal and N. Hernandez: The HIV-1 long terminal repeat contains an unusual element that induces the synthesis of short RNAs from various mRNA and snRNA promoters. Genes Dev 4, 2061-2074 (1990)

34. Toohey, M. G. and K. A. Jones: In vitro formation of short RNA polymerase II transcripts that terminate within the HIV-1 and HIV-2 promoter-proximal downstream regions. Genes Dev 3, 265-282 (1989)

35. Kashanchi, F., G. Piras, M. F. Radonovich, J. F. Duvall, A. Fattaey, C. M. Chiang, R. G. Roeder and J. N. Brady: Direct interaction of human TFIID with the HIV-1 transactivator tat. Nature 367, 295-299 (1994)

36. Jeang, K. T., R. Chun, N. H. Lin, A. Gatignol, C. G. Glabe and H. Fan: In vitro and in vivo binding of human immunodeficiency virus type 1 Tat protein and Sp1 transcription factor. J Virol 67, 6224-6233 (1993)

37. Parada, C. A. and R. G. Roeder: Enhanced processivity of RNA polymerase II triggered by Tat-induced phosphorylation of its carboxy-terminal domain. Nature 384, 375-378 (1996)

38. Mavankal, G., S. H. Ignatius Ou, H. Oliver, D. Sigman and R. B. Gaynor: Human immunodeficiency virus type 1 and 2 Tat proteins specifically interact with RNA polymerase II. Proc Natl Acad Sci U S A 93, 2089-2094 (1996)

39. Garcia-Martinez, L. F., D. Ivanov and R. B. Gaynor: Association of Tat with purified HIV-1 and HIV-2 transcription preinitiation complexes. J Biol Chem 272, 6851-6958 (1997)

40. Suñé, C., T. Hayashi, Y. Liu, W. S. Lane, R. A. Young and M. A. Garcia-Blanco: CA150, a nuclear protein associated with the RNA polymerase II holoenzyme, is involved in Tat-activated HIV-1 transcription. Mol Cell Biol 17, 6029-6039 (1997)

41. Cujec, T. P., H. Cho, E. Maldonado, J. Meyer, D. Reinberg and B. M. Peterlin: The human immunodeficiency virus transactivator Tat interacts with the RNA polymerase II holoenzyme. Mol Cell Biol 17, 1817-1823 (1997)

42. Colvin, R. A. and M. A. Garcia-Blanco: Unusual structure of the human immunodeficiency virus type 1 trans-activation response element. J Virol. 66, 930-935 (1992)

43. Colvin, R. A., S. W. White, M. A. Garcia-Blanco and D. W. Hoffman: Structural features of an RNA containing the CUGGGA loop of the human immunodeficiency virus type 1 trans-activation response element. Biochemistry 32, 1105-1112 (1993)

44. Harper, J. W. and N. J. Logsdon: Refolded HIV-1 tat protein protects both bulge and loop nucleotides in TAR RNA from ribonucleolytic cleavage. Biochemistry 30, 8060-8066 (1991)

45. Jaeger, J. A. and I. J. Tinoco: An NMR study of the HIV-1 TAR element hairpin. Biochemistry 32, 12522-12530 (1993)

46. Puglisi, J. D., R. Tan, B. J. Calnan, A. D. Frankel and J. R. Williamson: Conformation of the TAR RNA-arginine complex by NMR spectroscopy. Science 257, 76-80 (1992)

47. Calnan, B. J., B. Tidor, S. Biancalana, D. Hudson and A. D. Frankel: Arginine-mediated RNA recognition: the arginine fork. Science 252, 1167-1171 (1991)

48. Roy, S., U. Delling, C. H. Chen, C. A. Rosen and N. Sonenberg: A bulge structure in HIV-1 TAR RNA is required for Tat binding and Tat-mediated trans-activation. Genes Dev 4, 1365-1373 (1990)

49. Weeks, K. M., C. Ampe, S. C. Schultz, T. A. Steitz and D. M. Crothers: Fragments of the HIV-1 Tat protein specifically bind TAR RNA. Science 249, 1281-1285 (1990)

50. Garcia, J. A., D. Harrich, E. Soultanakis, F. Wu, R. Mitsuyasu and R. B. Gaynor: Human immunodeficiency virus type 1 LTR TATA and TAR region sequences required for transcriptional regulation. EMBO J 8, 765-778 (1989)

51. Gaynor, R., E. Soultanakis, M. Kuwabara, J. Garcia and D. S. Sigman: Specific binding of a HeLa cell nuclear protein to RNA sequences in the human immunodeficiency virus transactivating region. Proc Natl Acad Sci U S A 86, 4858-4862 (1989)

52. Cordingley, M. G., R. L. LaFemina, P. L. Callahan, J. H. Condra, V. V. Sardana, D. J. Graham, T. M. Nguyen, K. LeGrow, L. Gotlib, A. J. Schlabach and R. J. Colonno: Sequence-specific interaction of Tat protein and Tat peptides with the transactivation-responsive sequence element of human immunodeficiency virus type 1 in vitro. Proc Natl Acad Sci U S A 87, 8985-8989 (1990)

53. Dingwall, C., I. Ernberg, M. J. Gait, S. M. Green, S. Heaphy, J. Karn, A. D. Lowe, M. Singh, M. A. Skinner and R. Valerio: Human immunodeficiency virus 1 tat protein binds trans-activation-responsive region (TAR) RNA in vitro. Proc Natl Acad Sci U S A 86, 6925-6929 (1989)

54. Roy, S., N. T. Parkin, C. Rosen, J. Itovitch and N. Sonenberg: Structural requirements for trans-activation of human immunodeficiency virus type 1 long terminal repeat-directed gene expression by tat: importance of base pairing, loop sequence, and bulges in tat-responsive sequences. J Virol 64, 1402-1406 (1990)

55. Sumner-Smith, M., S. Roy, R. Barnett, L. S. Reid, R. Kuperman, U. Delling and N. Sonenberg: Critical chemical features in trans-acting-responsive RNA are required for interaction with human immunodeficiency virus type 1 tat protein. J Virol 65, 5196-5202 (1991)

56. Bohjanen, P. R., Y. Liu and M. A. Garcia-Blanco: TAR RNA decoys inhibit Tat-activated HIV-1 transcription after pre-initiation complex formation. Nucleic Acids Res 25, 4481-4486 (1997)

57. Herrmann, C. H. and A. R. Rice: Lentivirus Tat proteins specifically associate with a cellular protein kinase, TAK, that hyperphosphorylates the carboxyl-terminal domain of the large subunit of RNA polymerase II: candidate for a tat cofactor. J Virol 69, 1612-1620 (1995)

58. Garcia-Martinez, L. F., G. Mavankal, J. M. Neveu, W. S. Lane, D. Ivanov and R. B. Gaynor: Purification of a Tat-associated kinase reveals a TFIIH complex that modulates HIV-1 transcription. EMBO J 16, 2836-50 (1997)

59. Zhu, Y., T. Pe'ery, J. Peng, Y. Ramanathan, N. Marshall, T. Marshall, B. Amendt, M. B. Mathewa and D. H. Price: Transcription elongation factor P-TEFb is required for HIV-1 Tat transactivation in vitro. Genes Dev 11, 2622-2632 (1997)

60. Cujec, T. P., H. Okamoto, K. Fujinaga, J. Meyer, H. Chamberlin, D. O. Morgan and B. M. Peterlin: The HIV transactivator Tat binds to the CDK-activating kinase that activates the phosphorylation of the carboxy-terminal domain of RNA polymerase II. Genes Dev 11, 2645-2657 (1997)

61. Mancebo, Y. S. H., G. Lee, J. Flygare, J. Tomassini, P. Luu, Y. Zhu, J. Peng, C. Blau, D. Hazuda, D. Price and O. Flores: P-TEFb kinase is required for HIV Tat transcriptional activation in vivo and in vitro. Genes Dev 11, 2633-2644 (1997)

62. Cullen, B. R: Mechanism of action of regulatory proteins encoded by complex retroviruses. Microbiol Rev 56, 375-394 (1992)

63. Battiste, J. L., H. Mao, S. Rao, R. Tan, D. R. Muhandiram, L. E. Kay, A. D. Frankel and J. R. Williamson: Alpha helix-RNA major groove recognition in an HIV-1 Rev peptide-RRE RNA complex. Science 273, 1547-1551 (1996)

64. Daly, T. J., K. S. Cook, G. S. Gray, T. E. Maione and J. R. Rusche: Specific binding of HIV-1 recombinant Rev protein to the Rev-response element in vitro. Nature 342, 816-819 (1989)

65. Malim, M. H., J. Hauber, S.-Y. Le, J. V. Maizel and B. R. Cullen: The HIV-1 rev trans-activator acts through a structured target sequence to activate nuclear export of unspliced viral mRNA. Nature 338, 254-257 (1989)

66. Fischer, U., J. Huber, W. C. Boelens, I. W. Mattaj and R. Lührman: The HIV-1 Rev activations domain is a nuclear export signal that accesses an export pathway used by specific cellular RNAs. Cell 82, 475-483 (1995).

67. Wen, W., J. L. Meinkoth, R. Y. Tsien and S. S. Taylor: Identification of a signal for rapid export of proteins from nucleus. Cell 82, 463-473 (1995)

68. Stade, K., C. S. Ford, C. Guthrie and K. Weis: Exportin 1 (Crm1p) is an essential nuclear export factor. Cell 90, 1041-1050 (1997)

69. Fornerod, M., M. Ohno, M. Yoshida and I. W. Mattaj: CRM1 is an export receptor for leucine-rich nuclear export signals. Cell 90, 1051-1060 (1997)

70. Ullman, K. S., M. A. Powers and D. J. Forbes: Nuclear export receptors: From importin to exportin. Cell 90, 967-970 (1997)

71. Bogerd, H. P., R. A. Fridell, S. Madore and B. R. Cullen: Identification of a novel cellular cofactor for the rev/rex class of retroviral regulatory proteins. Cell 82, 485-494 (1995)

72. Stutz, F., M. Neville and M. Rosbash: Identification of a novel nuclear pore-associated protein as a functional target of the HIV-1 rev protein in yeast. Cell 82, 495-506 (1995)

73. Fritz, C. C., M. L. Zapp and M. R. Green: A human nucleoporin-like protein that specifically interacts with HIV Rev. Nature 376, 530-533 (1995)

74. Kestler, H. W., III, D. J. Ringler, K. Mori, D. L. Panicali, P. K. Sehgal, M. D. Daniel and R. C. Desrosiers: Importance of the nef gene for maintenance of high virus loads and for development of AIDS. Cell 65, 651-662 (1991)

75. Kerkau, T., R. Schmitt-Landgraf, A. Schimpl and E. Wecker: Downregulation of HLA class I antigens in HIV-1-infected cells. AIDS Res Hum Retroviruses 5, 613-620 (1989)

76. Scheppler, J. A., J. K. A. Nicholson, D. C. Swan, A. Ahmed-Ansari and J. S. McDougal: Down-modulation of MHC-I in a CD4+ T cell line, CEM-E5, after HIV-1 infection. J Immunol 143, 2858-2866 (1989)

77. Garcia, J. V. and A. D. Miller: Serine phosphorylation-independent downregulation of cell-surface CD4 by nef. Nature 350, 508-511 (1991)

78. Aiken, C., J. Konner, N. R. Landau, M. E. Lenburg and D. Trono: Nef induces CD4 endocytosis: Requirement for a critical dileucine motif in the membrane-proximal CD4 cytoplasmic domain. Cell 76, 853-864 (1994)

79. Schwartz, O., V. Maréchal, S. Le Gall, F. Lemonnier and J.-M. Heard: Endocytosis of major histocompatibility complex class I molecules is induced by the HIV-1 nef protein. Nature Med 2, 338-342 (1996)

80. Gulizia, R. J., R. G. Collman, J. A. Levy, D. Trono and D. E. Mosier: Deletion of nef slows but does not prevent CD4-positive T-cell depletion in human immunodeficiency virus type 1-infected human-PBL-SCID mice. J Virol 71, 4161-4164 (1997)

81. Debouck, C., T. A. Tomaszek Jr, L. A. Ivanoff and J. Culp: HIV protease. In: HIV. Biochemistry, molecular biology, and drug discovery. Ed: Karn, J., Oxford University Press, Oxford (1995)

82. Chen, B. K., R. T. Gandhi and D. Baltimore: CD4 down-modulation during infection of human T cells with human immunodeficiency virus type 1 involves independent activities of vpu, env and nef. J Virol 70, 6044-6053 (1996)

83. Simon, J. H. M., R. A. M. Fouchier, T. E. Southerling, C. B. Guerra, C. K. Grant and M. H. Malim: The vif and gag proteins of human immunodeficiency virus type 1 colocalize in infected human T cells. J Virol 71, 5259-5267 (1997)

84. Mann, R. and D. Baltimore: Varying the position of a retrovirus packaging sequence results in the encapsidation of both unspliced and spliced RNAs. J Virol 54, 401-407 (1985).

85. Lever, A., H. Gottlinger, W. Haseltine and J. Sodroski. Identification of a sequence required for efficient packaging of human immunodeficiency virus type 1 RNA into virions. J Virol 63, 4085-4087 (1989)

86. Rice, W. G., J. G. Supko, L. Malspeis, R. W. Buckheit, D. Clanton, M. Bu, L. Graham, C. A. Schaeffer, J. A. Turpin, J. Domagala, R. Gogliotti, J. P. Bader, S. M. Halliday, L. Coren, R. C. Sowder, L. O. Arthur and L. E. Henderson: Inhibitors of HIV nucleoprotein Zinc fingers as candidates for the treatment of AIDS. Science 270, 1194-1197 (1995)

87. Caputo, A., M. P. Grossi, C. Rossi, M. Betti, P. C. Marconi, G. Barbanti-Brodano and P. G. Balboni: Inhibition of HIV-1 replication and reactivation from latency by tat transdominant negative mutants in the cysteine rich region. Gene Therapy 3, 235-245 (1996)

88. Green, M., M. Ishino and P. M. Loewenstein: Mutational analysis of HIV-1 Tat minimal domain peptides: Identification of trans-dominant mutants that suppress HIV-LTR-driven gene expression. Cell 58, 215-223 (1989)

89. Pearson, L., J. Garcia, F. Wu, N. Modesti, J. Nelson and R. Gaynor: A transdominant tat mutant that inhibits tat-induced gene expression from the human immunodeficiency virus long terminal repeat. Proc Natl Acad Sci USA 87, 5079-5083 (1990)

90. Modesti, N., J. Garcia, C. Debouck, M. Peterlin and R. Gaynor: Trans-dominant Tat mutants with alterations in the basic domain inhibit HIV-1 gene expression. New Biol 3, 759-768 (1991)

91. Rice, A. P. and F. Carlotti: Mutational analysis of the conserved cysteine-rich region of the human immunodeficiency virus type 1 Tat protein. J Virol 64, 1864-1868 (1990)

92. Madore, S. J. and B. R. Cullen: Genetic analysis of the cofactor requirement for human immunodeficiency virus type 1 Tat function. J Virol 67, 3703-3711 (1993)

93. Orsini, M. J. and C. M. Debouck: Inhibition of human immunodeficiency virus type 1 and type 2 Tat function by transdominant Tat protein localized to both the nucleus and the cytoplasm. J Virol 70, 8055-8063 (1996)

94. Kamine, J., P. Loewenstein and M. Green: Mapping of HIV-1 Tat protein sequences required for binding to Tar RNA. Virology 182, 570-577 (1991)

95. Mhashilkar, , A. M., J. Bagley, S. Y. Chen, A. M. Szilvay, D. G. Helland and W. A. Marasco: Inhibition of HIV-1 Tat-mediated LTR transactivation and HIV-1 infection by anti-Tat single chain intrabodies. EMBO J 14, 1542-1551 (1995)

96. Biasolo, M. A., A. Radelli, L. Del Pup, E. Franchin, C. De Giuli-Morghen and G. Palu: A new antisense tRNA construct for the genetic tratment of human immunodeficiency virus type 1 infection. J Virol 70, 2154-2161 (1996)

97. Lo, K. M. S., M. A. Biasolo, G. Dehni, G. Palu and W. A. Haseltine: Inhibition of replication of HIV-1 by retroviral vectors expressing tat-antisense and anti-tat ribozyme RNA. Virology 190, 176-183 (1992).

98. Sun, L. Q., L. Wang, W. L. Gerlach and G. Symonds: Target sequence-specific inhibition of HIV-1 replication by ribozymes directed to tat RNA. Nucleic Acids Res 23, 2909-2913 (1995)

99. Chatterjee, S., P. R. Johnson and K. K. Wong Jr: Dual-target inhibition of HIV-1 in vitro by means of an adeno-associated virus antisense vector. Science 258, 1485-1488 (1992)

100. Marciniak, R. A., B. J. Calnan, A. D. Frankel and P. A. Sharp: HIV-1 Tat protein trans-activates transcription in vitro. Cell 63, 791-802 (1990)

101. Bohjanen, P. R., R. A. Colvin, M. Puttarju, M. D. Been and M. A. Garcia-Blanco: A small circular TAR RNA decoy specifically inhibits Tat-activated HIV-1 transcription. Nucleic Acids Res 24, 3733-3738 (1996)

102. Sullenger, B. A., H. F. Gallardo, G. E. Ungers and E. Gilboa: Analysis of trans-acting response decoy RNA-mediated inhibition of human immuodeficiency virus type 1 transactivation. J Virol 65, 6811-6816 (1991)

103. Sullenger, B. A., T. C. Lee, C. A. Smith, G. E. Ungers and E. Gilboa: Expression of chimeric tRNA-driven antisense transcripts renders NIH 3T3 cells highly resistant to Moloney murine leukemia virus replication. Mol Cell Biol 10, 6512-6523 (1990)

104. Lee, S. W., H. F. Gallardo, C. Smith and E. Gilboa: Inhibition of HIV-1 in CEM cells by a potent TAR decoy. Gene Ther 2, 377-384 (1995)

105. Lisziewicz, J., J. Rappaport and R. Dhar: Tat-regulated production of multimerized TAR RNA inhibits HIV-1 gene expression. New Biol 3, 82-89 (1991)

106. Lisziewicz, J., D. Sun, J. Smythe, P. Lusso, F. Lori, A. Louie, P. Markham, J. Rossi, M. Reitz and R. C. Gallo: Inhibition of human immunodeficiency virus type 1 replication by regulated expression of a polymeric Tat activation response RNA decoy as a strategy for gene therapy in AIDS. Proc Natl Acad Sci U S A 90, 8000-8004 (1993)

107. Lori, F., J. Lisziewicz, J. Smythe, A. Cara, T. A. Bunnag, D. Curiel and R. C. Gallo: Rapid protection against human immunodeficiency virus type 1 (HIV-1) replication mediated by high efficiency non-retroviral delivery of genes interfering with HIV-1 tat and gag. Gene Ther 1, 27-31 (1994)

108. Chang, H. K., R. Gendelman, J. Lisziewicz, R. C. Gallo and B. Ensoli: Block of HIV-1 infection by a combination of antisense tat RNA and TAR decoys: a strategy for control of HIV-1. Gene Ther 1, 208-216 (1994)

109. Lisziewicz, J., D. Sun, B. Trapnell, M. Thomson, H. K. Chang, B. Ensoli and B. Peng: An autoregulated dual-function antitat gene for human immunodeficiency virus type 1 gene therapy. J Virol 69, 206-212 (1995)

110. Lisziewicz, J., D. Sun, R. C. Gallo, B. Ensoli and F. Lori: Efficacy of antitat gene therapy in the presence of high multiplicity infection and inflammatory cytokines. Hum Gene Ther 7, 2209-16 (1996)

111. Lisziewicz, J., D. Sun, A. Lisziewicz and R. C. Gallo. Antitat gene therapy: a candidate for late-stage AIDS patients. Gene Ther 2, 218-222 (1995)

112. Rosenzweig, M., D. F. Marks, D. Hempel, J. Lisziewicz and R. P. Johnson: Transduction of CD34+ hematopoietic progenitor cells with an antitat gene protects T-cell and macrophage progeny from AIDS virus infection. J Virol 71, 2740-2746 (1997)

113. Malim, M. H., S. Bohnlein, J. Hauber and B. R. Cullen: Functional dissection of the HIV-1 Rev trans-activator - derivation of a trans-dominant repressor of Rev function. Cell 58, 205-214 (1989)

114. Escaich, S., C. Kalfglou, I. Plavec, S. Kaushal, J. D. Mosca and E. Bohnlein: RevM10-mediated inhibition of HIV-1 replication in chronically infected T cells. Hum Gene Ther 6, 625-634 (1995)

115. Liu, J., C. Wofferdin, Z. Y. Yang and G. J. Nabel: Regulated expression of a dominant negative form of rev improves resistance to HIV replication in T cells. Gene Ther 1, 32-37 (1994)

116. Malim, M. H., W. W. Freimuth, J. Liu, T. J. Boyle, H. K. Lyerly, B. R. Cullen and G. J. Nabel: Stable expression of transdominant Rev protein in human T cells inhibits human immunodeficiency virus replication. J Exp Med 176, 1197-1201 (1992)

117. Ragheb, J. A., P. Bressler, M. Daucher, L. Chiang, M. K. L. Chuah, T. Vandendriessche and R. A. Morgan: Analysis of trans-dominant mutants of the HIV type 1 rev protein for their ability to inhibit rev function, HIV type 1 replication, and their use as anti-HIV gene therapeutics. AIDS Res Hum Retroviruses 11, 1343-1353 (1995)

118. Wofferdin, C., Z. Y. Yang, Udaykumar, L. Xu, N. S. Yang, M. J. Sheeny and G. J. Nabel: Nonviral and viral delivery of a human immunodeficiency virus protective gene into primary human T cells. Proc Natl. Acad. Sci USA 91, 11581-11585 (1994)

119. Wofferdin, C., U. Ranga, Z. Y. Yang, L. Xu and G. J. Nabel: Expression of a protective gene prolongs survival of T cells in human immunodeficiency virus-infected patients. Proc Natl Acad Sci USA 93, 2889-2894 (1996)

120. Nabel, G. J., B. A. Fox, L. Post, C. B. Thompson and C. Wofferdin: A molecular genetic intervention for AIDS-Effects of a transdominant negative form of rev. Hum Gene Ther 5, 79-92 (1994)

121. Plavec, I., M. Agarwal, K. E. Ho, M. Pineda, J. Auten, J. Baker, H. Matsuzaki, S. Escaich, M. Bonyhadi and E. Böhnlein: High transdominant RevM10 protein levels are required to inhibit HIV-1 replication in cell lines and primary T cells: implication for gene therapy of AIDS. Gene Ther 4, 128-139 (1997)

122. Qian, X., Z. Chen, J. Zhang, A. B. Rabson and R. M. Krug: New approach for inhibiting REV function and HIV-1 production using the influenza virus NS1 protein. Proc Natl Acad Sci USA 93, 8873-8877 (1996)

123. Li, G., J. Lisziewicz, D. Sun, G. Zon, S. Daefler, F. Wong-Staal, R. C. Gallo and M. E. Klotman: Inhibition of Rev activity and human immunodeficiency virus type 1 replication by antisense oligodeoxynucleotide phosphothioate analogs directed against the Rev-response element. J Virol 67, 6882-6888 (1993)

124. Lisziewicz, J., D. Sun, M. Klotman, S. Agrawal, P. Zamecnik and R. Gallo: Specific inhibition of human immunodeficiency virus type 1 replication by antisense oligonucleotides: An in vitro model for treatment. Proc Natl Acad Sci USA 89, 11209-11213 (1992)

125. Sczakiel, G., M. Oppenlander, K. Rittner and M. Pawlita: Tat- and Rev-directed antisense RNA expression inhibits and abolishes replication of human immunodeficiency virus type 1: a temporal analysis. J Virol 66, 5576-5581 (1992)

126. Bahner, I., K. Kearns, Q. Hao, E. M. Smogorzewska and D. B. Kohn: Transduction of human CD34+ hematopoietic progenitor cells by a retroviral vector expressing an RRE decoy inhibits human immunodeficiency virus type 1 replication in myelomonocytic cells produced in long term culture. J Virol 70, 4352-4360 (1996)

127. Lee, T. C., B. A. Sullenger, H. F. Gallardo, G. E. Ungers and E. Gilboa: Overexpression of RRE-derived sequences inhibits HIV-1 replication in CEM cells. New Biol 4, 66-74 (1992)

128. Lee, S. W., H. F. Gallardo, E. Gilboa and C. Smith: Inhibition of Human Immunodeficiency Virus Type 1 in human T cells by a potent rev response element decoy consisting of the 13-nucleotide minimal rev-binding domain. J Virol 68, 8254-8264 (1994)

129. Smith, C., S.-W. Lee, E. Wong, H. Gallardo, K. Page, O. Gaspar, J. Lebkowski and E. Gilboa: Transient protection of human T-cells from human immunodeficiency virus type 1 infection by transduction with adeno-associated viral vectors which express RNA decoys. Antiviral Res 32, 99-115 (1996)

130. Good, P. D., A. J. Krikos, S. X. L. Li, E. Bertrand, N. S. Lee, L. Giver, A. Ellinton, J. A. Zaia, J. J. Rossi and D. R. Engelke: Expression of small, therapeutic RNAs in human cell nuclei. Gene Ther 4, 45-54 (1997)

131. Gottfredsson, M., T. Gentry, K. Phillips, S. Hull, E. Gilboa and C. Smith: Suppression of HIV-1 replication in human T cells transduced with an RNA decoy mimicking the rev binding domain of RRE (abstr. I15). In: Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology (1996)

132. Zhou, C., I. C. Bahner, G. P. Larson, J. A. Zaia, J. J. Rossi and D. B. Kohn: Inhibition of HIV-1 in human T-lymphocytes by retrovirally transduced anti-tat and rev hammerhead ribozymes. Gene 149, 33-39 (1994)

133. Duan, L., H. Zhang, J. W. Oakes, O. Bagasra and R. J. Pomerantz: Molecular and virological effects of intracellular anti-Rev single-chain variable fragments on the expression of various human immunodeficency virus-1 strains. Hum Gene Ther 5, 1315-1324 (1994)

134. Duan, L., O. Bagasra, M. A. Laughlin, J. W. Oakes and R. J. Pomerantz: Potent inhibition of human immunodeficiency virus type 1 replication by an intracellular anti-Rev single-chain antibody. Proc Natl Acad Sci USA 91, 5075-5079 (1994)

135. Wu, Y., L. Duan, M. Zhu, B. Hu, S. Kubota, O. Bagasra and R. J. Pomerantz: Binding of intracellular anti-rev single chain variable fragments to different epitopes of human immunodeficiency virus type 1 rev: Variations in viral inhibition. J Virol 70, 3290-3297 (1996)

136. Kubota, S., L. Duan, R. A. Furuta, M. Hatanaka and R. J. Pomerantz: Nuclear preservation and cytoplasmic degradation of human immunodeficiency virus type 1 Rev protein. J Virol 70, 1282-1287 (1996)

137. Bonyhadi, M. L., K. Moss, A. Voytovich, J. Auten, C. Kalfoglou, I. Plavec, S. Forestell, L. Su, E. Böhnlein and H. Kaneshima: RevM10-expressing T cells derived in vivo from transduced human hematopoietic stem-progenitor cells inhibit human immunodeficiency virus replication. J Virol 71, 4707-4716 (1997)

138. Inouye, R. T., B. Du, D. Boldt-Houle, A. Ferrante, I.-W. Park, S. M. Hammer, L. Duan, J. E. Groopman, R. J. Pomerantz and E. F. Terwilliger: Potent inhibition of human immunodeficiency virus type 1 in primary T cells and alveolar macrophages by a combination anti-Rev strategy delivered in an adeno-associated virus vector. J Virol 71, 4071-4078 (1997)

139. Yamada, O., G. Kraus, M. C. Leavitt, M. Yu and F. Wong-Staal: Activity and cleavage site specificity of an anti-HIV-1 hairpin ribozyme in human T cells. Virology 205, 121-126 (1994)

140. Deacon, N. J., A. Tsykin, A. Solomon, K. Smith, M. Ludford-Menting, D. J. Hooker, D. A. McPhee, A. L. Greenway, A. Ellett, C. Chatfield, V. A. Lawson, S. Crowe, A. Maerz, S. Sonsa, J. Learmont, J. S. Sullivan, A. Cunningham, D. Dwyer, D. Dowton and J. Mills: Genomic structure of an attenuated quasi species of HIV-1 from a blood transfusion donor and recipients. Science 270, 988-991 (1995)

141. Larsson, S., G. Hotchkiss, J. Su, T. Kebede, M. Andäng, T. Nyholm, B. Johansson, A. Sönnerborg, A. Vahlne, S. Britton and L. Ährlund-Richter: A novel ribozyme target site located in the HIV-1 Nef open reading frame. Virology 219, 161-169 (1996)

142. Yu, M., E. Poeschla, O. Yamada, P. Degrandis, M. C. Leavitt, M. Heusch, J. K. Yees, F. Wong-Staal and A. Hampel: In vitro and in vivo characterization of a second functional hairpin ribozyme against HIV-1. Virology 206, 381-386 (1995)

143. Maciejewski, J. P., F. F. Weichold, Y. N. S, A. Cara, D. Zella, M. S. Reitz Jr and R. C. Gallo: Intracellular expression of antibody fragments directed against HIV reverse transcriptase prevents HIV infection in vitro. Nature Med 1, 667-673 (1995)

144. Bordier, B., C. Helene, P. J. Barr, S. Litvak and L. Sarih-Cottin: In vitro effect of antisense oligonucleotides on human immunodeficiency virus type 1 reverse transcription. Nucleic Acids Res 20, 5999-6006 (1992)

145. Craigie, R., A. B. Hickman and A. Engelman: Integrase. In: HIV. Biochemistry, molecular biology, and drug discovery. Ed: Karn, J., Oxford University Press, Oxford 2, 53-71 (1995).

146. Sioud, M. and K. Drlica: Prevention of human immunodeficiency virus type 1 integrase expression in Escherichia coli by a ribozyme. Proc Natl Acad Sci USA 88, 7303-7307 (1991)

147. Levy-Mintz, P., L. Duan, H. Zhang, B. Hu, G. Dornadula, M. Zhu, J. Kulkosky, D. Bizub-Bender, A. M. Skalka and R. J. Pomerantz: Intracellular expression of single-chain variable fragments to inhibit early stages of the viral life cycle by targeting human immunodeficiency virus type 1 integrase. J Virol 70, 8821-8832 (1996)

148. Babé, L. M., J. Rosé and C. S. Craik: Trans-dominant inhibitory immunodeficiency virus type 1 protease monomers prevent protease activation and virion maturation. Proc Natl Acad Sci USA 92, 10069-10073 (1995)

149. Junker, U., S. Escaich, I. Plavec, J. Baker, F. McPhee, J. R. Rosé, C. S. Craik and E. Böhnlein: Intracellular expression of human immunodeficiency virus type 1 (HIV-1) protease variants inhibits replication of wild-type and protease inhibitor-resistant HIV-1 strains in human T-cell lines. J Virol 70, 7765-7772 (1996)

150. Serio, D., T. A. Rizvi, M. Cartas, V. S. Kalyanaraman, I. T. Weber, H. Koprowski and A. Srinivasan: Dvelopment of a novel anti-HIV-1 agent from within: Effect of chimeric Vpr-containing protease cleavage site residues on virus replication. Proc Natl Acad Sci USA 94, 3346-3351 (1997)

151. Trono, D., M. B. Feinberg and D. Baltimore: HIV- gag mutants can dominantly interfere with the replication of the wild-type virus. Cell 59, 113-120 (1989)

152. Sczakiel, G., M. Pawlita and A. Kleinheinz: Specific inhibition of human immunodeficiency virus type 1 replication by RNA transcribed in sense and antisense from the 5'-leader/gag region. Biochem Biophys Res Comm 169, 643-651 (1990)

153. Sczakiel, G. and M. Pawlita: Inhibition of human immunodeficiency virus type 1 replication in human T cells stably expressing antisense RNA. J Virol 65, 468-472 (1991)

154. Veres, G., S. Escaich, J. Baker, C. Barske, C. Kalfoglou, H. Ilves, H. Kaneshima and E. Böhnlein: Intracellular expression of RNA transcripts complementary to the human immunodeficiency virus type 1 gag gene inhibits viral replication in human CD4+ lymphocytes. J Virol 70, 8792-8800 (1996)

155. Sarver, N., E. M. Cantin, P. S. Chang, J. A. Zaia, P. A. Ladne, D. A. Stephens and J. J. Rossi: Ribozymes as potential anti-HIV-1 therapeutic agents. Science 247, 1222-1225 (1990)

156. Schumann, G., L. Qin, A. Rein, G. Natsoulis and J. D. Boeke: Therapeutic effect of gag-nuclease fusion protein on retrovirus-infected cell cultures. J Virol 70, 4329-4337 (1996)

157. Schumann, G., K. Cannon, W.-P. Ma, R. J. Crouch and J. D. Boeke: Antiretroviral effect of a gag-RNase HI fusion gene. Gene Ther 4, 593-599 (1997)

158. Mebatsion, T., S. Finke, F. Weiland and K.-K. Conzelman: A CXCR4/CD4 psudotype rhabdovirus that selectively infects HIV-1 envelope protein-expressing cells. Cell 90, 841-847 (1997)

159. Schnell, M. J., J. E. Johnson, L. Buonocore and J. K. Rose: Construction of a novel virus that targets HIV-1-infected cells and controls HIV-1 infection. Cell 90, 849-857 (1997)

160. Schnierle, B. S., J. Stitz, V. Bosch, F. Nocken, H. Merget-Millitzer, M. Engelstädter, R. Kurth, B. Groner and K. Cichutek: Pseudotyping of murine leukemia virus with the envelope glycoproteins of HIV generates a retroviral vector with specificity of infection for CD4-expressing cells. Proc Natl Acad Sci USA 94, 8640-8645 (1997)

161. Marasco, W. A., W. A. Haseltine and S. Chen: Design, intracellular expression, and activity of a human anti-human immunodeficiency virus type 1 gp120 single-chain antibody. Proc Natl Acad Sci USA 90, 7889-7893 (1993)

162. Chen, C., -J., A. C. Banerjea, G. G. Harmison, K. Haglund and M. Schubert: Multitarget-ribozyme directed to cleave at up to nine highly conserved HIV-1 env RNA regions inhibits HIV-1 replication - potential effectiveness against most presently sequenced HIV-1 isolates. Nucleic Acids Res 20, 4581-4589 (1992)

163. Wu, X., H. Liu, H. Xiao, J. Kim, P. Seshaiah, G. Natsoulis, J. D. Boeke, B. H. Hahn and J. C. Kappes: Targeting foreign proteins to human immunodeficiency virus particles via fusion with vpr and vpx. J Virol 69, 3389-3398 (1995)

164. Ojwang, J. O., A. Hampel, D. J. Looney, F. Wong-Staal and J. Rappaport: Inhibition of human immunodeficiency virus type 1 expression by a hairpin ribozyme. Proc Natl Acad Sci USA 89, 10802-10806 (1992)

165. Dropulic, B., N. H. Lin, M. A. Martin and K.-T. Jeang: Functional characterization of a U5 ribozyme: Intracellular suppression of human immunodeficiency virus type 1 expression. J Virol 66, 1432-1441 (1992)

166. Yamada, O., M. Yu, J. K. Yee, G. Kraus, D. Looney and F. Wong-Staal: Intracellular immunization of human T cells with a hairpin ribozyme against human immunodeficiency virus type 1. Gene Ther 1, 38-45 (1994)

167. Yu, M., J. Ojwang, O. Yamada, A. Hampel, J. Rapapport, D. Looney and F. Wong-Staal. A hairpin ribozyme inhibits expression of diverse strains of human immunodeficiency virus Type 1. Proc Natl Acad Sci USA 90, 6340-6344 (1993)

168. Weerasinghe, M., S. E. Liem, S. Asad, S. E. Read and S. Joshi: Resistance to human immunodeficiency virus type 1 (HIV-1) infection in human CD4+ lymphocyte-derived cell lines conferred by using retroviral vectors expressing an HIV-1 RNA-specific ribozyme. J Virol 65, 5531-5534 (1991)

169. Leavitt, M. C., M. Yu, O. Yamada, G. Kraus, D. Looney, E. Poeschla and F. Wong-Staal: Transfer of an anti-HIV-1 ribozyme gene into primary human lymphocytes. Hum Gene Ther 5, 1115-1120 (1994)

170. Yu, M., M. C. Leavitt, M. Maruyama, O. Yamada, D. Young, A. D. Ho and F. Wong-Staal: Intracellular immunization of human fetal cord blood stem/progenitor cells with a ribozyme against human immunodeficiency virus type 1. Proc Natl Acad Sci USA 92, 669-703 (1995)

171. Sun, L. -Q., D. Warrilow, L. Wang, C. Witherington, J. Macpherson and G. Symonds: Ribozyme-mediated suppression of Moloney murine leukemia virus and human immunodeficiency virus type I replication in permissive cell lines. Proc Natl Acad Sci USA 91, 9715-9719 (1994)

172. Hamouda, T., R. McPhee, S.-C. Hsia, G. S. Read, T. C. Holland and S. R. King: Inhibition of human immunodeficiency virus replication by the herpes simplex virion shutoff protein. J Virol 71, 5521-5527 (1997)

173. Caruso, M. and D. Klatzmann: Selective killing of CD4+ cells harboring a human immunodeficiency virus-inducible suicide gene prevents viral spread in an infected population. Proc Natl Acad Sci USA 89, 182-186 (1992)

174. Brady, H. J. M., C. G. Miles, D. J. Pennington and E. A. Dzierzak: Specific ablation of human immunodeficiency virus Tat-expressing cells by conditionally toxic retroviruses. Proc Natl Acad Sci USA 91, 356-369 (1994)

175. Venkatesh, L. K., M. Q. Arens, T. Subramanian and G. Chinnadurai: Selective inhibition of toxicity to human cells expressing human immunodeficiency virus type 1 Tat by a conditionally cytotoxic adenovirus vector. Proc Natl Acad Sci USA 87, 8746-8750 (1990)

176. Harrison, G. S., C. J. Long, T. J. Curiel, F. Maxwell and I. H. Maxwell: Inhibition of human immunodeficiency virus-1 production resulting from transduction with a retrovirus containing an HIV-regulated diphteria toxin A chain gene. Hum Gene Ther 3, 461-469 (1992)

177. Harrison, G. S., C. J. Long, F. Maxwell, L. M. Glode and I. H. Maxwell: Inhibition of HIV production in cells containing an integrated, HIV-regulated diphteria toxin A chain gene. AIDS Res Hum Retroviruses 8, 39-45 (1992)

178. Winters, M. A. and T. C. Merigan: Continuous presence of CD4-PE40 is required for antiviral activity against single-passage HIV isolates and infected peripheral blood mononuclear cells. AIDS Res Hum Retroviruses 9, 1091-1096 (1993)

179. Mhashilkar, A. M., D. K. Biswas, J. LaVecchio, A. B. Pardee and W. A. Marasco: Inhibition of human immunodeficiency virus type 1 replication in vitro by a novel combination of anti-Tat single-chain intrabodies and NF-kB antagonists. J Virol 71, 6486-6494 (1997)

180. Yuyama, N., J. Ohkawa, T. Koguma, M. Shirai and K. Taira: A multifunctional expression vector for an anti-HIV-1 ribozyme that produces a 5'- and 3'-trimmed trans-acting ribozyme, targeted against HIV-1 RNA, and cis-acting ribozymes that are designed to bind to and thereby sequester trans-activator proteins such as Tat and Rev. Nucleic Acids Res 22, 5060-5067 (1994)

181. Lisziewics, J., D. Sun, J. Smythe, P. Lusso, F. Lori, A. Louie, P. Markham, J. Rossi, M. Reitz and R. C. Gallo: Inhibition of human immunodeficiency virus type 1 replication by regulated expression of polymeric Tat activation response RNA decoy as a strategy for gene therapy in AIDS. Proc Natl Acad Sci USA 90, 8000-8004 (1993)

182. Yamada, O., G. Kraus, L. Luznik, M. Yu and F. Wong-Staal: A chimeric human immunodeficiency virus type 1 (HIV-1) minimal rev response element-ribozyme molecule exhibits dual antiviral function and inhibits cell-cell transmission of HIV-1. J Virol 70, 1596-1601 (1996)

183. Gervaix, A., X. Li, G. Kraus and F. Wong-Staal: Multigene antiviral vectors inhibit diverse human immunodeficiency virus type 1 clades. J Virol 71, 3048-3053 (1997)

184. Aguilar-Cordova, E. C., J. Chinen, L. Donehower, J. W. Harper, J. S. Butel and J. W. Belmont: Inhibition of HIV-1 by a double transdominant fusion gene. Gene Ther 2, 181-186 (1995)

185. Chinen, J., E. Aguilar-Cordova, D. Ng-Tang, D. E. Lewis and J. W. Belmont: Protection of primary human T cells from HIV infection by Trev: A transdominant fusion gene. Hum Gene Ther 8, 861-868 (1997)

186. Ulich, C., D. Harrich, P. Estes and R. B. Gaynor: Inhibition of Human Immunodeficiency Virus Type 1 replication is enhanced by a combination of transdominant tat and rev proteins. J Virol 70, 4871-4876 (1996).

187. Ramezani, A., S. F. Ding and S. Joshi: Inhibition of HIV-1 replication by retroviral vectors expressing monomeric and multimeric hammerhead ribozymes. Gene Ther 4, 861-867 (1997)

188. Ohkawa, J., N. Yuyama, Y. Takebe, S. Nishikawa and K. Taira: Importance of independence in ribozyme reactions: Kinetic behavior of trimmed and simply connected ribozymes with potential activity against human immunodeficiency virus. Proc Natl Acad Sci USA 90, 11302-11306 (1993)

189. Liu, D., J. Donegan, G. Nuovo, D. Mitra and J. Laurence: Stable human immunodeficiency virus type 1 (HIV-1) resistance in transformed CD4+ monocytic cells treated with multitargeting HIV-1 antisense sequences incorporated into U1 snRNA. J Virol 71, 4079-4085 (1997)

190. Duan, L., M. Zhu, I. Ozaki, H. Zhang, D. L. Wei and R. J. Pomerantz: Intracellular inhibition of HIV-1 replication using a dual protein- and RNA-based strategy. Gene Ther 4, 533-543 (1997)

191. Dean, M., M. Carrington, C. Winkler, G. A. Huttley, M. W. Smith, R. Allikmets, J. J. Goedert, S. P. Buchbinder, E. Vittinghoff, E. Gomperts, S. Donfield, D. Vlahov, R. Kaslow, A. Saah, C. Rinaldo, R. Detels and S. J. O'Brien: Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Science 273, 1856-1862 (1996)

192. Walker, R. E: A phase I/II pilot study of the safety of the adoptive transfer of syngeneic gene-modified cytotoxic T lymphocytes in HIV-infected identical twins. Hum Gene Ther 7, 367-400 (1996)

193. Sanhadji, K., P. Leissner, R. Firouzi, F. Pelloquin, L. Kehrli, M. Marigliano, V. Calenda, M. Ottmann, J. C. Tardy, M. Mehtali and J. L. Touraine: Experimental gene therapy: the transfer of Tat-inducible interferon genes protects human cells against HIV-1 challenge in vitro and in vivo in severe combined immunodeficient mice. AIDS 11, 977-86 (1997)

194. Hammer, S. M., K. E. Squires, M. D. Hughes, J. M. Grimes, L. M. Demeter, J. S. Currier, J. J. Eron, Jr., J. E. Feinberg, H. H. Balfour, Jr., L. R. Deyton, J. A. Chodakewitz and M. A. Fischl: A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med 337, 725-33 (1997)